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ABSTRACT 
Marie-Josèphe Horner: Cancer Burden Among HIV-Infected Persons on Antiretroviral Therapy in Malawi: 
A Record Linkage Study 
(Under the direction of Andrew Olshan) 
 
Sub-Saharan Africa represents 70% of the global number of people living with HIV. The regional HIV 
epidemic is reflected in the cancer burden, where AIDS-defining cancers are among the most common 
malignancies in the region. Early access and continued adherence to antiretroviral therapy (ART) may 
reduce the risk of certain cancers among the HIV population. Local epidemiological data are needed to 
characterize the cancer burden among African HIV populations during the ART era.  
In the Malawi HIV-Cancer Match Study, we used algorithms to link cancer cases from the population-
based cancer registry of Malawi with electronic medical records from two high volume HIV clinics. We 
constructed a clinical cohort of 29,000 people who initiated ART from 2000 to 2010 at Lighthouse Trust 
and Queen Elizabeth Central Hospital. We described implementation of a healthcare data linkage in a 
resource-constrained setting, common analytical barriers, and solutions. We used Poisson regression to 
estimate cancer incidence rates and describe the timing of new cancer diagnoses after starting ART.  
Missing data and misreporting of patient identifiers resulted in a substantial proportion of potential 
cancer cases being discarded from analysis. Consequently, missing data on potential cancer cases may 
have diminished sensitivity of the linkage algorithms. Sensitivity analysis of incidence rates was used to 
address scenarios of uncertainty in the linkage process.   
Two AIDS-defining malignancies, Kaposi sarcoma (KS) and cervical cancer, were the most common 
cancers in this young population of ART users who tend to present to care with severe 
immunosuppression. Most incident KS occurred within the first two years of starting ART, and elevated 
incidence rates persisted over the course of follow-up in spite of therapy. AIDS-associated non-Hodgkin 
lymphomas and a heterogeneous spectrum of NADC were also observed, but at low incidence rates.  
Our study is a baseline against which to monitor the contemporary burden of cancer among people 
who are now starting ART at earlier stages of HIV, when therapy likely to have a substantial impact on 
iv 
cancer incidence. Descriptive epidemiological data on people living with HIV is important for public health 




TABLE OF CONTENTS 
LIST OF TABLES ......................................................................................................................................... ix 
LIST OF FIGURES ....................................................................................................................................... xi 
LIST OF ABBREVIATIONS.......................................................................................................................... xii 
CHAPTER I. SPECIFIC AIMS....................................................................................................................... 1 
CHAPTER 2. BACKGROUND ...................................................................................................................... 4 
 HIV infection, immunodeficiency, inflammation and risk of cancer .......................................... 4 
Hallmarks of HIV infection ........................................................................................................ 4 
CD4 cell counts and cancer risk ............................................................................................... 4 
Hallmarks of cancer: evasion of immune destruction and tumor-promoting 
inflammation ............................................................................................................................. 6 
 Epidemiology of cancer in the HIV/AIDS population ................................................................ 8 
 Evolution of the cancer burden during the HAART era .......................................................... 11 
 The HIV epidemic and ART scale-up in Sub-Saharan Africa ................................................ 12 
 Cancer burden among the HIV/AIDS population in sub-Saharan Africa ............................... 16 
 Overview of the Malawi HIV-Cancer Match Study ................................................................. 27 
 Summary and public health significance ................................................................................ 27 
CHAPTER 3. RESEARCH DESIGN AND METHODS ............................................................................... 29 
 Study design ........................................................................................................................... 29 
 Study populations ................................................................................................................... 29 
ART cohorts ........................................................................................................................... 29 
Malawi cancer registry............................................................................................................ 31 
Inclusion and exclusion criteria for record linkage ................................................................. 32 
 Background on probabilistic record linkage ........................................................................... 32 
Overview ................................................................................................................................ 32 
vi 
Linkage variables ................................................................................................................... 33 
Linkage methods overview ..................................................................................................... 33 
Definitions of m and u conditional probabilities ...................................................................... 34 
Record classification .............................................................................................................. 37 
Outcome misclassification in probabilistic record linkage ...................................................... 37 
 Specific Aim 1 ......................................................................................................................... 39 
Statistical analysis specific aim 1.1 ........................................................................................ 45 
 Specific Aim 2 ......................................................................................................................... 46 
Inclusion and exclusion criteria for analytic dataset ............................................................... 46 
Outcome definition ................................................................................................................. 47 
Person-time definition............................................................................................................. 47 
Covariates .............................................................................................................................. 47 
Descriptive statistics ............................................................................................................... 48 
Statistical analysis specific aim 2 ........................................................................................... 48 
 Sensitivity analysis ................................................................................................................. 49 
CHAPTER 4. OPPORTUNITIES AND BARRIERS TO BIG DATA APPROACHES IN 
GLOBAL HEALTH: A CASE-STUDY OF HIV-CANCER RECORD LINKAGE IN MALAWI ....................... 51 
A. Introduction ............................................................................................................................. 51 
 Methods .................................................................................................................................. 52 
Populations ............................................................................................................................. 52 
Record linkage study design .................................................................................................. 53 
Match variables ...................................................................................................................... 53 
Probabilistic data linkage ....................................................................................................... 53 
Data harmonization and pre-processing ................................................................................ 54 
Highest weight classification of records ................................................................................. 55 
Outcome validation ................................................................................................................. 56 
Post-processing ...................................................................................................................... 57 
Statistical analysis .................................................................................................................. 57 
vii 
 Results ................................................................................................................................... 58 
Linkage performance.............................................................................................................. 58 
Data completeness and quality .............................................................................................. 58 
Bias analysis .......................................................................................................................... 59 
Onomastics ............................................................................................................................ 59 
 Discussion .............................................................................................................................. 60 
 Conclusions ............................................................................................................................ 62 
CHAPTER 5. HIGH CANCER BURDEN AMONG ANTIRETROVIRAL THERAPY USERS 
IN MALAWI: A RECORD LINKAGE STUDY USING OBSERVATIONAL HIV COHORTS 
AND CANCER REGISTRY DATA .............................................................................................................. 74 
 Introduction ............................................................................................................................. 74 
 Methods .................................................................................................................................. 75 
Populations ............................................................................................................................. 75 
Electronic medical record linkage .......................................................................................... 75 
Study design and statistical analysis ...................................................................................... 76 
 Results ................................................................................................................................... 77 
AIDS-defining cancers............................................................................................................ 78 
Non-AIDS-defining cancers .................................................................................................... 78 
 Discussion .............................................................................................................................. 79 
E. Supplementary materials ....................................................................................................... 87 
Highest weight classification and validation ........................................................................... 88 
Sensitivity analysis ................................................................................................................. 93 
CHAPTER 6. CONCLUSIONS ................................................................................................................... 94 
A. Summary of findings............................................................................................................... 94 
 Public health implications ....................................................................................................... 95 
 Strengths ................................................................................................................................ 97 
 Limitations .............................................................................................................................. 98 
 Conclusions and future directions ........................................................................................ 100 
  
viii 
APPENDIX A. STANDARDIZED INCIDENCE RATIOS ........................................................................... 103 
APPENDIX B. CUMULATIVE RISK OF CANCER AMONG NEW ART USERS ...................................... 104 
APPENDIX C. TEMPORAL TRENDS IN INCIDENCE OF KAPOSI SARCOMA ..................................... 107 
REFERENCES .......................................................................................................................................... 112 
  
ix 
LIST OF TABLES  
Table 2-1. Associations between CD4 cell count, timing of CD4 measurement, and 
duration of immunosuppression and cancer risk .......................................................................................... 5 
Table 2-2. Summary of direct and indirect mechanisms of the innate and adaptive arms 
of immune system regulation during cancer immunosurveillance and immunoediting................................. 8 
Table 2-3. Summary of meta-analysis standardized incidence ratios (SIR) and 95%CI 
among HIV/AIDS patients and organ transplant recipients relative to the general 
population .................................................................................................................................................... 10 
Table 2-4. Population-level studies of the cancer burden among the HIV/AIDS population 
and trends during ART expansion in sub-Saharan Africa ........................................................................... 21 
Table 3-1. Coverage of ART initiators by city and region ........................................................................... 30 
Table 3-2. Concepts of m and u probabilities illustrated with an epidemiology 2-by-2 table ...................... 35 
Table 3-3. Summary of workflow in probabilistic record linkage ................................................................. 40 
Table 3-4. Covariates .................................................................................................................................. 47 
Table 3-5. Definitions of ART person-time, cancer outcomes, and limitations of each 
analytic approach in Specific Aim 2 ............................................................................................................ 50 
Table 4-1. Completeness of identifiers used in probabilistic matching ....................................................... 64 
Table 4-2. Missing characteristics across link fields during each step of the record linkage 
process, Lighthouse Trust ........................................................................................................................... 65 
Table 4-3. Missing characteristics across link fields during each step of the record linkage 
process, Queen Elizabeth Central Hospital ................................................................................................ 66 
Table 4-4. Degree of similarity across link fields during each step of the record linkage 
process, Lighthouse Trust ........................................................................................................................... 67 
Table 4-5. Degree of similarity across link fields during each step of the record linkage 
process, Queen Elizabeth Central Hospital ................................................................................................ 68 
Table 4-6. Association of individual-level characteristics among matched and non-
matched records, Lighthouse Trust ............................................................................................................ 69 
Table 5-1. Characteristics of naïve ART initiators enrolled at Lighthouse Trust HIV Clinic 
(2007-2010) and Queen Elizabeth Hospital HIV clinic (2000-2010). .......................................................... 83 
Table 5-2. Cancer incidence rates by timing of diagnosis after ART initiation ........................................... 85 
Table 5-3. Cancer incidence rates and incidence ratios by WHO clinical stage ........................................ 86 
Table 5-4. Frequency of observed cancers by HIV clinical cohort.............................................................. 89 
Table 5-5. Cancer incidence rates by HIV clinical cohort ........................................................................... 92 
Table 5-6. Sensitivity analysis: site-specific cancer incidence rates, by HIV clinical cohort ....................... 93 
x 
Appendix A Table 1. Standardized incidence ratios for AIDS-defining cancers (2007-2010 
only) ........................................................................................................................................................... 103 
Appendix B Table 1. Cancer prevalence at ART start (Lighthouse Trust) ................................................ 104 
Appendix B Table 2. Cumulative incidence of ever cancer among ART users, Lighthouse 
Trust .......................................................................................................................................................... 105 
Appendix C Table 1. Kaposi sarcoma and cervical cancer incidence rates by WHO 
clinical stage, early versus late timing of cancer diagnosis, and calendar period of ART 
initiation ..................................................................................................................................................... 109 
Appendix C Table 2. Individuals at risk and ART person-years at risk for incident cancer, 
by WHO stage and calendar period .......................................................................................................... 110 
  
xi 
LIST OF FIGURES 
Figure 2-1. HIV prevalence in sub-Saharan Africa, by sex and urban/rural residence .............................. 13 
Figure 2-2. Trends in ART coverage, number of ART clinics, and ART guideline criteria 
during pre-ART and post-ART national scale-up in Malawi ........................................................................ 15 
Figure 2-3. Incidence of Kaposi Sarcoma in Africa, by country and sex. IARC 
GLOBOCAN 2012 ....................................................................................................................................... 17 
Figure 2-4. Incidence of cervical cancer in Africa, by country. IARC GLOBOCAN 2012 ........................... 17 
Figure 2-5. Incidence of non-Hodgkin lymphoma in Africa, by country and sex. IARC 
GLOBOCAN 2012 ....................................................................................................................................... 18 
Figure 3-1. Geographic and temporal coverage of cancer by the cancer registry in 
relation to the ART cohorts ......................................................................................................................... 29 
Figure 3-2. Iterative linkage process for generating m and u probabilities ................................................. 43 
Figure 3-3. Definitions of lost to follow-up dates in ART study cohorts ...................................................... 48 
Figure 3-4. Hypothetical patient timeline for sensitivity analysis of prior ART exposure ............................ 49 
Figure 4-1. Record linkage workflow ........................................................................................................... 70 
Figure 4-2. Flowchart of cancer registry linkage to HIV patient records (A: Lighthouse 
Trust; B: Queen Elizabeth Central Hospital) ............................................................................................... 71 
Figure 4-3. Highest weight classification of linkage outcomes as a function of perfect and 
partial agreement (A: Lighthouse Trust; B: Queen Elizabeth Central Hospital) ......................................... 72 
Figure 4-4. Highest weight classification of linkage outcomes as a function of perfect and 
partial agreement and distribution of surnames in HIV cohorts (A: Lighthouse Trust; B: 
Queen Elizabeth Central Hospital) .............................................................................................................. 73 
Figure 5-1. Site-specific cancer incidence rates, by HIV clinical cohort ..................................................... 84 
Figure 5-2. Flowchart of cancer registry linkage to Queen Elizabeth Central Hospital .............................. 87 
Figure 5-3. Flowchart of cancer registry linkage to Lighthouse Trust ......................................................... 87 
Appendix B Figure 1. Incidence of cancer among 30-year old ART users: modified 
Kaplan Meier versus standard approach .................................................................................................. 105 
Appendix C Figure 1. Person-years at risk for cancer, by WHO clinical stage, calendar 
period, and cohort ..................................................................................................................................... 111 
  
xii 
LIST OF ABBREVIATIONS 
ADC  AIDS-defining cancer 
AIDS  acquired immunodeficiency syndrome 
ART  antiretroviral therapy 
CI   confidence interval 
EMR  electronic medical record 
HAART  highly active anti-retroviral therapy 
HBV  hepatitis B virus 
HCV  hepatitis C virus 
HIV  human immunodeficiency virus 
HPV  human papilloma virus 
IARC   International Agency for Research on Cancer, Lyon, France 
IeDEA  International epidemiologic Databases to Evaluate AIDS 
IR  incidence rate 
IRR  incidence rate ratio 
KS  Kaposi sarcoma 
LT  Lighthouse Trust ART clinic, Lilongwe 
NADC  non-AIDS-defining cancer 
NHL   non-Hodgkin lymphoma 
NHSRC  Malawi National Health Sciences Research and Ethics Committee 
QECH  Queen Elizabeth Central Hospital ART clinic, Blantyre 
SIR  standardized incidence ratio 
SSA   sub-Saharan Africa 
WHO  World Health Organization 
 
1 
CHAPTER I. SPECIFIC AIMS 
The African HIV epidemic is reflected in a heavy burden of AIDS-defining cancers (ADC), with 
Kaposi sarcoma (KS), non-Hodgkin lymphoma (NHL), and cervical cancer being among the most 
common malignancies in sub-Saharan Africa (SSA).1, 2  Eastern and Southern regions in SSA have 
implemented rapid scale-up of HIV treatment, and 10 countries have achieved greater than 80% ART 
coverage over the past decade.3  Yet the extent to which contemporary ART availability is impacting the 
African cancer burden remains largely unknown. Since the introduction of combination ART regimens in 
the West in the mid-1990s and highly active antiretroviral therapy (HAART) in 19974 the burden and 
incidence rates of KS and NHL have declined substantially.5-8 Incidence declines for NADC have been 
much more modest, and NADC burden has actually increased with growth and aging of HIV-infected 
populations, as well as declines in competing causes of death.7, 9 It remains to be seen whether the 
cancer trends among persons living with HIV in developed countries10 will be replicated in Africa, as 
epidemiological  studies from the region are limited in quality and number.11-13 
Given typically low-quality data sources for robust epidemiological studies in SSA, innovative 
approaches are required to overcome cancer surveillance obstacles in low- and middle-income countries. 
Electronic linkage of medical records is an efficient strategy for constructing observational patient cohorts, 
yet methods to implement this approach in low- and middle-income countries have not been well 
described. Our goal is to address the central knowledge gap of how to implement data linkage strategies 
in a resource-limited setting to construct a locally relevant data resource for evaluating cancer burden 
among people living with HIV in Africa.  
Our proposal focuses on Malawi, where HIV prevalence is 11% and ART coverage has currently 
reached 67% among guideline-eligible HIV patients; one in 20 Malawian adults is currently on ART.14, 15  
Expanded eligibility criteria among adults include WHO stage 1 or 2 and CD4 counts ≤500 cells/mm3, 
WHO stage 3 or 4 regardless of CD4 count, and universal ART for HIV-infected pregnant and 
breastfeeding women (Option B+).16 With respect to malignancies, cervical cancer and KS feature as the 
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most common cancer types among women and men, respectively17. UNC-Project Malawi has long-
standing collaborations with the Malawian government and in-country stakeholders for HIV and cancer 
care and research. These provide a strong foundation to implement this new initiative, which is the basis 
of this dissertation project: the Malawi HIV-Cancer Match Study. The study is innovative in that it will 
leverage a hybrid of probabilistic algorithms and extensive clerical review to link data from Malawi’s 
national cancer registry with electronic medical systems created to support antiretroviral therapy delivery 
within large HIV cohorts. Record linkage using existing data is a cost-efficient strategy for resource-
constrained environments and imposes no additional burden on local health care workers in Malawi. The 
hybrid method will be locally tailored to overcome real-world limitations of missing data and lack of unique 
identifiers in low- and middle-income countries. Further epidemiological  methods will be applied to 
assess and account for potential outcome misclassification errors resulting in false positive matches 
(records that linked erroneously) and false negative matches (records that failed to link).18, 19  
This large-scales study creates a new data resource to answer high impact public health questions 
regarding the effect of real-world ART delivery on cancer incidence and the clinical timing of cancer 
development among persons living with HIV in SSA. Characterization of contributing factors and patterns 
of cancer occurrence in HIV populations using high-quality data derived from within the region, rather 
than extrapolating from studies conducted in resource-rich settings, will be valuable for informing 
evidence-based national cancer control efforts.  Our specific aims seek to characterize cancer incidence 
patterns among contemporary ART initiators in Malawi, while accounting for measurement error in a 
statistically rigorous way: 
Specific Aim 1. Adapt, implement, and evaluate a hybrid approach of probabilistic-deterministic 
linkage methods suited to health systems in a resource-limited setting.     
Subaim 1.1. Linkage methodology will be delineated in the context of locally relevant ethnographic 
considerations and missing data in low- and middle-income countries. Our study is a proof of concept of 
an innovative health systems approach tailored to cancer surveillance in SSA.   
Subaim 1.2. Describe associations between missing data and data accuracy on linkage weights.  
Missing data and lack of resolution among patient identifiers may cause measurement error in HIV-cancer 
match status and may introduce bias in subsequent analyses. The use of probabilistic algorithms alone in 
 
3 
low- and middle-income settings may be overly conservative in assigning HIV-cancer matches due to 
underlying missing data in the local health systems.   
Specific Aim 2. Characterize cancer incidence rates and clinical timing of cancer diagnosis relative 
to ART start.  
The Malawi HIV-Cancer Match Study is uniquely positioned to link data from high quality population-
based cancer registration and well-established ART cohorts participating in the International 
epidemiologic Databases to Evaluate AIDS (IeDEA) consortium. Our newly constructed resource 
incorporates patient-level clinical data enriched with active patient follow-up, WHO stage of HIV, ART 
regimens, and population-based cancer ascertainment meeting data quality standards for Cancer in V 
Continents (IARC, Lyon).20  
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CHAPTER 2. BACKGROUND  
 HIV infection, immunodeficiency, inflammation and risk of cancer 
Hallmarks of HIV infection  
People living with HIV have a greater risk of certain cancers compared to the general population and 
this association is largely due to profound immunodeficiency and co-infections with oncogenic viruses 5, 9, 
21-28. Three hallmarks of HIV infection are implicated in various pathways of cancer development: immune 
deficiency, chronic inflammation and immune system activation, and immune senesence29, 30. As HIV 
progresses, CD4+ T lymphocytes become increasingly depleted. Chronic immune activation and 
sustained inflammation are triggered. Lastly, the immune system of people living with HIV also shares a 
feature normally seen with old age: loss of regenerative capacity, or senescence30. Senescence drives 
the increased risk of cancer associated with aging31, 32. The effects of HIV- associated chronic 
inflammation and dysfunction of the immune system show similarities with cellular aging33. Inflammation 
and depleted CD4 cell counts often persist despite ART, and despite viral suppression, but at lower levels 
than untreated people32, 34. Together these findings have public health implications for managing the risk 
of cancer among persons living with HIV.  
CD4 cell counts and cancer risk  
Mechanistically, the question of how immunodeficiency contributes to cancer risk is more nuanced. 
Low CD4 cell count is inversely associated with risk of KS and NHL35-37. A remaining question is whether 
current CD4 cell count or the duration of immunodeficiency is what drives increased cancer risk, 
particularly for NADC (Table 2-1).  The effect size of the association between CD4 levels on NADC 






Table 2-1. Associations between CD4 cell count, timing of CD4 measurement, and duration of immunosuppression and cancer risk 
Outcome  Association Definition of CD4 exposure 
measurement 
Incidence rate and distribution of cancer 
types 
Grouped NADC Inverse association, especially 
among virally-associated cancers, 
with lower CD4 count 38-41, even 
after adjusting for smoking, alcohol 
use, and co-infections with 
Hepatitis B virus or Hepatitis C 
Virus. Initial ART drug class was 
not associated with NADC 38. 
Deaths from NADC was inversely 
associated with CD4 counts 42. HIV 
viremia was not associated with 
increased risk of NADC 43. 
Agence Nationale de Recherche sur le 
SIDA (ANRS) CO3 Aquitaine Cohort40 
used CD4<500 cut point 
 
AIDS Clinical Trials Group trials38 used 
time-updated CD4 count; 25% had 
CD4<350  
EuroSIDA cohort41 used current CD4  
D:A:D Study cohort 42 used most recent 
CD4 stratifying by counts <50 to >500 
in Poisson modeling  
In the Italian cohort 39 the incidence of ADC 
was 5.0 per 1000 person-years (95%CI 
4.3, 5.8) and 2.4 per 1000 person-years 
(95%CI 1.9, 3.1) for NADC.  
 
In the EuroSIDA cohort, the incidence of 
NADC was 4.3 per 1000 person years 
(95%CI 3.8, 4.7).  48% of NADC were 
virus-related, 38% were non-virus-related 
epithelial cancers, and 14% were ‘other’.  
 
In the D:A:D Study, the ADC mortality 
among those with a CD4 count <50 was 20 
per 1000 person-years (95%CI: 14.4, 25.9) 
compared to 0.1 (95%CI 0.03, 0.3) among 
those with CD4 count >500; NADC 
mortality was 6.0 (95%CI 3.3, 10.1) and 0.6 




Inverse association between with 
CD4 count and elevated HPV viral 
load, HPV persistence, 
precancerous lesions  





Inverse association with low CD4 
at baseline45, low CD4 at onset of 
AIDS46, long duration of low CD4 
count43, 47, low nadir CD448.  
 
13 North American cohorts6 , 
AIDS-cancer match46 , U.S. 
Military Natural History Study48 
 
French Hospital Database on HIV 
cohort47 used current CD4 (most 
predictive among 72 models). Rate 
ratios using CD4>500 as referent and 
categories of CD4 counts 350-499 and 
<50 
 
AIDS Therapy Evaluation in the 
Netherlands (ATHENA) cohort43 used 
time-updated CD4 and HIV viral load 
and cumulative exposure time to CD4 
counts of < 200, < 350,  < 500 and viral 
load >50, >400, and >1000 copies/mL 
Risk of HPV associated cancers increased 
with increasing levels of 
immunosuppresion46. SIRs compared HIV-
infected and non-infected people  
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Hallmarks of cancer: evasion of immune destruction and tumor-promoting inflammation   
The hallmarks of cancer represent a unifying view of processes that enable the development and 
proliferation of tumors 49, 50. The classic etiologic framework recognizes tumorigenesis as a multistep 
process of cellular evolution in which normal and aberrant cells participate in complex interactions with 
the tumor microenvironment in which they grow. Many types of cells and features comprise the 
microenvironment: extracellular scaffolding, stromal compartments, cancer stem cells, endothelial cells, 
pericytes which synthesize vascular membranes, cytokine and chemokine cellular signaling chemicals, 
and immune inflammatory cells. Though different tumor types possess their own district set of etiologic 
mechanisms, it is recognized that there is a set of hallmark functional capabilities that are required for 
cancers to proliferate, survive, and metastasize. The six classic hallmark traits are self-sufficiency in 
growth signals, insensitivity to growth suppressors, evasion of apoptosis, limitless replicative potential, 
sustained angiogenesis, and tissue invasion and metastasis. Deregulation of cellular metabolism and 
evasion of immune destruction are now recognized as additional emerging hallmark capabilities50. 
Underlying these traits, genomic instability in tumor cells and a state of tumor-promoting inflammation are 
recognized as two critical enabling characteristics for acquiring hallmark cancer traits.   
The enabling characteristic of inflammation plays a dualistic role in tumor- microenvironment 
interactions51 . Paradoxically, immune inflammatory cells both antagonize and enhance the acquisition of 
hallmark capabilities among newly formed aberrant cells, a phenomenon that is not entirely 
counterintuitive considering the wound-healing properties of inflammation51. Cells from the innate arm of 
the immune system interact with the microenvironment by releasing growth factor signals, pro-angiogenic 
factors, signals to control programmed cell death, as well as enzymes that are used in remodeling 
extracellular scaffolding and promoting tissue proliferation -- all of which are also hallmark capabilities that 
enhance neoplastic initiation, proliferation, and invasion. But while wound-healing inflammation is 
generally transient, various degrees of chronic inflammation in the tumor microenvironment have been 
observed along the full spectrum of neoplastic transformation, from the early stages of pre-malignant 
tumor lesions through advanced stage cancer. In fact, observations of tumor infiltration by white blood 
cells led to the analogy of tumors as “wounds that never heal” 52. Compounding the problem is that 
inflammatory cells also release reactive oxygen species into the tumor microenvironment. Reactive 
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oxygen species are mutagenic, and therefore add momentum in generating even further genomic 
instability among neoplastic cells.  
The emerging hallmark of evasion of immune destruction by cancers has its roots in the early 
observations of immune system suppression of tumor growth by Elrich in 1909 and later theories of 
immunosurveillance by immunologists Burnet and Thomas in the 1950s53-55. They postulate a constant 
monitoring of cells and tissues by the immune system which recognize tumor cell-specific antigens and 
then attack nascent tumor cells. The early theory assumed that cancers arise through an acquired 
capability of evading detection by the immune system, though we now understand that 
immunosurveillance56 is just one step in the larger scheme of immunoediting of tumors by the immune 
system57-59.  
Immunoediting has three 3 phases: elimination, equilibrium, and escape 57. Direct and indirect 
mechanisms of the innate and adaptive arms of the immune system play important roles in cancer 
immunosurveillance and immunoediting (Table 2-2)51. The elimination phase refers to the role of 
immunosurveillance as an extrinsic tumor suppressor.  The ability of the immune system to distinguish 
tumor cells predominantly comes from CD4+ and CD8+ T lymphocytes which recognize Major 
Histocompatibility Complex (MHC) class I and II proteins, though many other receptors and molecules are 
also involved in recruiting innate and adaptive immune effectors 57.  Tumor specific cell-surface antigensa 
presented on MHC proteins arise from the expression of mutated oncogenes, aberrant expression of self- 
proteins, and even certain viral proteins among cell types harboring these viruses59-61. Highly antigenic 
tumor cells are effectively pared down through components of both the innate and adaptive arms of the 
immune systemb, the process known as elimination. Equilibrium is the phase during which incomplete 
tumor destruction gives rise to weakly antigenic cellular clones that persist in tumor immune-mediated 
                                                     
a Tumor antigens can be broadly grouped according to 1) differentiation antigens, e.g., melanocyte differentiation 
antigens, Melan-A/MART-1, tyrosinase, gp-100; (2) mutational antigens, e.g., abnormal forms of p53; (3) 
overexpressed/amplified antigens, e.g.,HER-2/neu; (4) cancer-testis (CT) antigens, e.g., MAGE and NY-ESO-1; (5) 
viral antigens, e.g., EBV and HPV. 
b The innate immune system is the “first line of defense” against pathogens such as bacteria. The innate arm is 
comprised of mast cells, granulocytes, natural killer cells, and tumor-infiltrating phagocytic macrophages and 
neutrophils (known as inflammatory cells). Inflammatory cells also play a role in directing the adaptive arm of the 
immune system. The adaptive arm is comprised of lymphocytes which undergo clonal selection for antigen-specific 
receptors. The adaptive arm is involved in immunologic memory.23 
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latency 57. In the escape phase, tumors exit equilibrium and begin to proliferate and infiltrate by subverting 
normal innate and adaptive anti-tumor defenses.  
 
Table 2-2. Summary of direct and indirect mechanisms of the innate and adaptive arms of immune 
system regulation during cancer immunosurveillance and immunoediting  
Innate immunity Adaptive immunity 
Direct mechanisms 
Induction of DNA damage by reactive oxygen 
species and free radicals 
Inhibition of tumor growth by antitumor cytotoxic-
T-cell activity 
Paracrine regulation of intracellular pathways via 
nuclear factor κB 
Inhibition of tumor growth by cytokine-mediated 
lysis of tumor cells 
Indirect mechanisms 
Promotion of angiogenesis and tissue 
remodeling by the production of growth 
factors, cytokines, chemokines and matrix 
metalloproteinases 
Promotion of tumor growth by regulatory T cells 
that suppress antitumor T-cell responses 
 
Cyclooxygenase-2 (COX-2) upregulation Promotion of tumor development by humoral 
immune responses that increase chronic 
inflammation in the tumor microenvironment 
Suppression of antitumor adaptive immune 
responses 
 
*adapted from Visser et al 2008 
 
 Epidemiology of cancer in the HIV/AIDS population  
The overall distribution of cancers in the HIV population is skewed, with Kaposi sarcoma, cervical 
cancer and central nervous system lymphoma, three AIDS-defining cancers (ADC), featuring prominently. 
The HIV population is also at increased risk of non-AIDS defining cancers (NADC), particularly those 
associated with viral co-infections22, 27, 28, 62-64. Virally-associated cancers include Kaposi sarcoma and 
human herpes-virus 8 (HHV-8); subtypes of Hodgkin and non-Hodgkin lymphomas and Epstein Barr virus 
(EBV); cervical and subsets of anal, oropharyngeal cancers and human papilloma virus (HPV); liver 
cancer and hepatitis B and C viruses (HBV, HCV).  
Advanced immune suppression, chronic inflammation and viral co-infection are important drivers of 
the increased risk of malignancies among people living with HIV 28, 64. An important meta-analysis seeking 
to elucidate the role of immune deficiency compared the incidence of a broad range of cancer types in 
HIV patients and in organ transplant recipients to the general population20. These two patient groups 
share the common characteristic of immune deficiency, but presumably no other commonalities: organ 
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transplant recipients receive pharmacologically-induced immune suppressors to prevent transplant 
rejection while HIV patients ultimately succumb to profound immunodeficiency in the absence of 
antiretroviral therapy. In the 7 population-based studies of HIV patients, most were followed after onset of 
AIDS. Cancer incidence rates were elevated in both patient groups relative to the general population for 
the majority of the 28 cancers under investigation, suggesting that immune deficiency is driving the 
association. It is noteworthy that the 15 cancer types with infectious etiologies (Epstein-Barr virus, human 
herpesvirus 8, hepatitis B and C viruses, human papillomavirus, and Helicobacter pylori) all had elevated 
rates (Table 2-3). The rate of Kaposi sarcoma among HIV patients was 3640-times higher that of the 
general population, the rate of NHL was 77 times higher, and the rate of cervical cancer was 6 times 
higher. Rates were also 29 times higher for anal cancer, 11 times higher for Hodgkin lymphoma, and 6 
times higher for liver cancer. Oncogenic viruses themselves have direct effects on cancer induction63 and 
these are exacerbated by immunosuppression through persistence of infection, uncontrolled viral 
replication, and uncontrolled latent infections. Together, impaired ability of the immune system to control 
infection and a higher prevalence of HPV and HBV co-infections among people living with HIV drive the 
elevated occurrence of these infection-related cancers65.  
The HIV population does not exhibit a greater risk of non-infection related, common epithelial 
cancers compared to the general population 22, 23, 28, 64. The rates of breast and colorectal cancers, both 
epithelial cancers, were not elevated compared to the general population, with standardized incidence 
ratios (SIR) generally close to one28. The rate of prostate cancer was 30% lower among the HIV 
population28, 66. Ovarian cancer had modest, significantly elevated rates. Though HIV patients experience 
chronic immunodeficiency arising primarily through deficits of T and B cells, they may still possess some 
functionality of the innate immune system (e.g. natural killer cells) to partially suppress cancer 
development, at least for non-infection related epithelial cancers. Rates of lung cancer were 3 times 
higher, and thought to be due to the higher prevalence of smoking in the HIV population67-69. Higher rates 
of other smoking-related cancers, kidney (SIR=1.7) and laryngeal cancers (SIR=1.5), were found in a 
subsequent meta-analysis64. However, the association between HIV and lung cancer persists 
independently of smoking70-73 , suggesting that other factors could be important as well. Frequent 
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pulmonary infections and chronic inflammation may also be associated with the greater occurrence of 
lung cancer among the HIV population 74.  
 
Table 2-3. Summary of meta-analysis standardized incidence ratios (SIR) and 95%CI among HIV/AIDS 
patients and organ transplant recipients relative to the general population 
Infectious agent Infection-related or 
possibly-related cancer 
site 
HIV cohort  
SIR (95% CI) 
Transplant cohort 
SIR (95%CI) 
Epstein-Barr Virus Hodgkin’s lymphoma 11.03 (8.43-14.4) 3.89 (2.42-6.26) 
Non-Hodgkin lymphoma 76.67 (39.4-149) 9.07 (6.40-10.2) 
Human Herpes Virus-8 Kaposi sarcoma 3640.0 (3326-3976) 208.0 (114-349) 
Hepatitis B Virus 
Hepatitis C Virus 
Liver cancer 5.22 (3.32-8.20) 2.13 (1.16-3.91) 
Helicobacter pylori Stomach cancer 1.09 (1.53-2.36) 2.04 (1.49-2.79) 
Human papilloma viruses Cervix uteri 5.82 (2.98–11.3) 2.13 (1.37–3.30) 
Vulva vagina 6.45 (4.07–10.2) 22.76 (15.8–32.7) 
Penis 22.76 (15.8–32.7) 15.79 (5.79–34.4) 
Anus 28.75 (21.6–38.3) 4.85 (1.36–17.3) 
Oral cavity and pharynx (a 
subset are possibly 
related) 
2.32 (1.65–3.25) 3.23 (2.40–4.35) 
Non-melanoma skin 
(possibly related) 
4.11 (1.08–16.6) 28.62 (9.39–87.2) 
Lip (possibly related) 2.80 (1.91–4.11) 30.00 (16.3–55.3) 
Esophagus (possibly 
related, though current 
evidence supporting this 
association is equivocal) 
1.62 (1.20–2.19) 3.05 (1.87–4.98) 
 
Larynx (possibly related) 2.72 (2.29–3.22) 1.99 (1.23–3.23) 
Eye (possibly related) 1.98 (1.03–3.81) 6.94 (3.49–13.8) 
Non-infection related epithelial cancers HIV cohort  
SIR (95% CI) 
Transplant cohort 
SIR (95%CI) 
 Breast 1.03 (0.89-1.20) 1.15 (0.98-1.36) 
Prostate 0.70 (0.55-0.89) 0.97 (0.78-1.19) 
Ovary 1.63 (0.95-2.80) 1.55 (0.99-2.43) 
Colon, rectum 0.92 (0.78-1.08) 1.69 (2.34-2.43) 
 Lung 2.72 (1.91-3.87) 2.18 (1.85-2.57) 
* adapted from Grulich et al 2007 
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 Evolution of the cancer burden during the HAART era 
A major public health question is whether ART reduces the risk of HIV-associated cancers and 
NADC over time 75. ART has improved immunocompetence and reduced the risk of AIDS, AIDS-related 
deaths and all-cause mortality76-79. In parallel, the cancer burden in the HIV population has also begun to 
evolve- combination ART has caused a dramatic shift in the number of new cancer cases and distribution 
of cancer types in the HIV/AIDS population, though the incidence rates of many cancers remain elevated 
relative to the general population5, 9, 28, 64, 80.  Since the introduction of combination ART regimens in early 
1990s and highly active antiretroviral therapy (HAART) in 1996, the burden and incidence rates of KS and 
NHL have declined substantially5-8, while the burden of NADC has increased7, 9.  
In a study of cancer trends during the pre-HAART through late HAART period in the HIV/AIDS 
Cancer Match Study, the number of incident KS cases decreased by 82% and NHL by 53% over a 15 
year period from 1991-20059. Incidence rates for KS and NHL decreased sharply during 1991-1997, and 
more gradually through 2005. On the other hand, the number of cervical cancer cases increased by 62%, 
though the incidence rate had declined.  
In the AIDS population, the overall incidence of NADC declined over time but trends were not 
uniform across cancer sites9. Incidence rates of Hodgkin lymphoma, liver, lung, and colorectal cancers 
declined or remained constant, while rates of anal and prostate cancer incidence increased. The 
increased incidence rate of prostate cancer occurred against a backdrop of declining incidence in the 
general population81.  Overall, substantial increases in the absolute burden of NADC in the late HAART 
period were observed: anal cancer, lung cancer, prostate cancer, Hodgkin lymphoma and liver cancer, 
together accounted for 50% of the NADC burden, yet account these sites account for less than 20% in 
the general population 82. The burden of prostate and colorectal cancers, which are considered to be non-
HIV-related epithelial cancers, also increased significantly. The burden of uterine, vulva, and cervical 
cancer also increased.  
Demographic changes are largely responsible for trends in the cancer burden: growth of the AIDS 
population has more than quadrupled in size in the US, and consequently increased number of people at 
risk9. Meanwhile, aging of the HIV/AIDS population has shifted at risk persons into a demographic where 
the risk of many NADC is greater7, 9, 10. Of note, the majority of prostate cancers occurred among those 
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older than 50 years old in the HIV/AIDS Cancer Match Study. In the late HAART era, NADC represent 
50% of malignancies in the HIV-only population, with lung cancer accounting for 20% of the total cancer 
burden. The number of NADC now exceed that of ADC among the AIDS population in the US, though KS 
continues to dominate as the most common specific cancer type9. 
Despite many clinical gains through the introduction of HAART in 1996, prognosis after a cancer 
diagnosis remains poor. Compared to their HIV-uninfected counterparts, patients with HIV present with 
more advanced cancer stage at diagnosis83 , experience worse survival77, and have higher cancer-
specific mortality84-86. Lung, breast, prostate, melanoma, and bladder cancers are more likely to be 
diagnosed at distal stages, highlighting potentially distinct tumorigenic mechanisms related to immune 
suppression that we still do not fully understand,  and potential barriers in access to medical care among 
the HIV population83. Cancer deaths have declined due to HAART, but because of the decrease in overall 
mortality, malignancies now represent a growing proportion of total deaths among HIV/AIDS populations 
in developed countries78, 87. Cancer accounts for nearly one-third of deaths in the HIV/AIDS population88.  
Cancer-specific mortality remains elevated compared to the HIV-uninfected cancer patient population, 
independently of cancer stage at diagnosis and receipt of treatment86.    
 The HIV epidemic and ART scale-up in Sub-Saharan Africa 
Sub-Saharan Africa is at the center of the HIV epidemic with 25.6 million people affected in 2015, 
representing 70% of the global HIV burden for only 15% of the world’s population89, 90 . Two-thirds of new 
HIV infections occur in SSA. Within the region, there is geographic heterogeneity in the intensity of the 
epidemic: 9 countries in Southern Africa have the highest prevalence and together represent one-third of 
the global number of people living with HIV/AIDS. Swaziland, Botswana and Lesotho have the most 
severe epidemic with HIV prevalences between 23%-26% among adults; Malawi, Mozambique, Namibia, 
South Africa, Zambia and Zimbabwe have HIV prevalences exceeding 10%. Within-country variability 




Figure 2-1. HIV prevalence in sub-Saharan Africa, by sex and urban/rural residence 
Source: World Health Organization. Global Health Observatory data repository. Accessible at: 
http://apps.who.int/gho/data/node.main.247?lang=en  [Accessed on August 17, 2016] 
 
 
Over the past decade, global partnerships with the WHO, donors, and local governments, combined 
with competitive bidding to reduce the cost of antiretroviral drugs, have led to a major expansion of 
access to ART in Africa. Though many obstacles and gaps still remain in the implementation of HIV 
prevention and treatment in SSA, there have also been notable successes.  As of the 2010 WHO 
guidelines, more than 10 SSA countries have exceed 80% ART coverage3 and this figure is expected to 
increase as a greater number of people are now eligible under the new WHO guidelines91. In the latest 
UNAIDS Gap Report, nearly 50% of persons living with HIV in SSA know their status. Among these, 87% 
are receiving ART, and 75% of those on treatment have achieved viral suppresion92. These initiatives 
have translated to 7.6 million people receiving ART as of 2012, and nearly 5 million lives saved in 
Africa89. Because ART also prevents transmission of HIV by up to 96%93, the paradigm of treatment as 
prevention has in turn translated to a reduction in new HIV infections by more than 50% in Malawi, 
Botswana, Ethiopia, Namibia, Rwanda, Zambia and Zimbabwe, and reductions of more than 25% in 
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HIV prevalence in Malawi is 10.6%, with the highest prevalence reaching 14.5% in southern districts 
and 22.5% among urban women15. Demographically, Malawi ranks 174 on the Human Development 
Index, the most recent estimate of average life expectancy at birth is 62.8 years, and gross national 
income per capita is less than one US dollar per day95, 96. Prior to the implementation of ART programs, 
life expectancy declined from 54 years to 39 years in 2000, and this has been directly attributed to the 
rampant, uncontrolled HIV epidemic97.  
In many ways, Malawi has been a leader in nationwide scale-up of ART to tackle the epidemic. In 
2002, Malawi made a successful bid to the Global Fund for AIDS, Tuberculosis and Malaria, to receive 
funds in support of a national response to HIV, including the purchase of antiretroviral drugs. Prior to 
scale up, in only 1,220 patients were receiving ART at KCH and QECH, Malawi’s two central hospitals in 
Lilongwe and Blantyre, respectively, and a rural district hospital in Chiradzulu97. Over the following years, 
the Ministry of Health and Population and the National AIDS Commission implemented nationwide scale-
up of ART, beginning in the Northern districts and working towards the South97. Since Malawi began 
implementing free ART in 2004,  ART delivery rose from 2-3% to 67% coverage among eligible HIV  
patients in 2014 14, 98, representing more than a half million people who are now receiving therapy. Latest 
estimates show over 700 ART clinics in operation throughout the country (Figure 2-2). ART programs in 
Malawi now include life-long, universal access of ART for pregnant women Option B+, lay counselors for 




Figure 2-2. Trends in ART coverage, number of ART clinics, and ART guideline criteria during pre-ART 
and post-ART national scale-up in Malawi  
 
* Data on the number of ART clinics were approximated for year 2012. Regrettably, the exact number of clinics were 
not retrievable for 2012. 
2002: Malawi bids to the Global Fund for AIDS, Tuberculosis and Malaria (http://www.theglobalfund.org/en/) The 
Ministry of Health and Population, with the assistance of the National AIDS Commission, prepares to scale-up ART.  
2004: ART national scale-up is initialized 
2003 to 2006: national ART eligibility: WHO stage 3/4 or CD4-lymphocytes<200/mm3 or WHO stage 2 with total 
lymphocyte count (TLC) <1200 cells/μl (Reference: Treatment of Aids Guidelines for the Use of Antiretroviral Therapy 
in Malawi. First Edition: September 2003. National AIDS Commission of Malawi and Ministry of Health and 
Population, Malawi) 
2006: ART eligibility raised to CD4<250 cell/mm3 
2008: ART eligibility for adults >15 years: HIV+ and WHO clinical stage 3/4 or CD4-lymphocyte count <250/mm3 or 
WHO clinical stage 2 with TLC 1200/mm3. ART eligibility for Children ≤14 years: HIV+ and WHO pediatric clinical 
stage3/4 or CD4-lymphocyte percent<threshold or WHO pediatric stage 2 with TLC< threshold (Reference: 
Guidelines for the Use of Antiretroviral Therapy in Malawi, Third Edition: April 2008. Ministry of Health, Malawi) 
July 2011: ART eligibility for adults increased the threshold to CD4< 350 cell/mm3. Option B+  made ART available  to 
all HIV+ pregnant women for the rest of their lives, regardless of CD4 count or clinical staging (Reference: Clinical 
Management of HIV in Children and Adults. Malawi Integrated Guidelines For Providing HIV In Antenatal Care, 
Maternity Care, Under 5 Clinics, Family Planning Clinics, Exposed Infant/Pre-ART Clinics, ART Clinics. First Edition. 
July 2011. Ministry of Health, Malawi) 
April 2014: new guidelines for HIV clinical management require ART for all HIV+ children < 5years; HIV+ children >5 
years or adults with CD4<500 or those co-infected with Hepatitis B. Therefore the number of children and adults 
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  Cancer burden among the HIV/AIDS population in sub-Saharan Africa 
Cancer is a public health concern in Africa. Non-communicable diseases now feature among the 
leading causes of death. After heart disease, cancer is the 7th leading causes of mortality, accounting for 
approximately half a million deaths annually, or 4% of total mortality in SSA99. HIV/AIDS continues to be 
the leading cause of death in SSA, accounting for 1.7 million deaths (14.3%). The future cancer burden in 
Africa is expected to double to 1.3 million new cases and 970,000 deaths by 2030 83, a trend that is 
strongly driven by aging of the population, population growth, and the adoption of Western risk factors 
including smoking, physical inactivity, obesity, and diet1, 100. Population projections expect the 
demographic over the age of 65 will account for 4.5% of the population structure in 2030 and 10% by 
2050; simultaneously, unprecedented growth in the youth population is predicted101, 102. By 2030, the 
population structure in many African regions will resemble that of industrialized nations102. Against this 
backdrop, it is increasingly relevant to adopt cancer control programs that are tailored to countries with 
low resources103. 
The current cancer burden in SSA is remarkably different from that of industrialized countries in 
terms of the distribution of cancer types, stage at diagnosis, incidence, mortality, and patient survival2. 
HIV-associated cancers represent a high burden in Eastern and Southern SSA as a direct reflection of 
the rampant HIV epidemic (Figure 2-3, Figure 2-4, Figure 2-5). Three AIDS-defining malignancies, KS, 
cervical cancer, and NHL are among the top 10 types of cancers presenting in the region1, 83. In Malawi, 
KS and cervical cancer are the most common cancers among men and women, respectively104. It is 
recognized that the HIV epidemic and cancer burden are interconnected in SSA, yet African data from the 
field of population sciences is sorely needed to guide cancer prevention measures targeting persons 
living with HIV/AIDS.    
Population-based cancer data required for evidence-based cancer control programs in SSA is direly 
lacking105-107. Only 1% of Africa’s population is covered by 5 population-based cancer registries that meet 
IARC’s data quality standards of completeness, validity, and timeliness in reporting20. Routine cancer 
surveillance is crucial for informing evidence-based cancer control, guiding health policy, and planning the 
allocation of clinical care. Pathology services are considered the backbone of cancer surveillance, yet 
population coverage by pathology services in Sub-Saharan Africa is only one-tenth that in resource-
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replete settings108.  Limited health infrastructure and cancer diagnostic services further hinder the process 
of formally and completely ascertaining cancer incidence. Lastly, because HIV is not a reportable disease 
in many African countries and due to the local poor health infrastructure, HIV status is not routinely 
collected by cancer registries, or other public health registries. At the same time, cancer outcomes are not 
routinely collected by ART clinics, with the exception of KS and cervical cancer, which are, by definition, 
clinical indications of stage 4 HIV/AIDS.    
 
Figure 2-3. Incidence of Kaposi Sarcoma in Africa, by country and sex. IARC GLOBOCAN 2012  
 
 








To overcome these logistical setbacks, ecologic studies, HIV-cancer record linkages, and registry-
based descriptive studies have been the main epidemiological  approaches to assess the impact of ART 
scale-up on recent cancer incidence and to assess the cancer burden among persons living with 
HIV/AIDS in select SSA countries (Table 2-4). Two recent ecologic studies in Uganda13 and Botswana11, 
109 sought to examine the impact of recent ART scale-up on cancer incidence rates and to estimate the 
proportion of cancer cases living with HIV. By using a subsample of the registry with known HIV status, 
the Botswana study used inverse probability weighting to assign HIV status among all cancer cases in the 
registry. The Uganda study used cancer outcomes classified by ADC and NADC since HIV status was 
unknown among cancer cases. In Botswana, 61% of the total cancer cases in the registry occurred 
among HIV-positive people. As ART coverage increased from 7% to 82% over a five year period, the 
incidence rate of all cancers among HIV-positive cases declined by 8% per year. The incidence of KS 
among HIV-positive cases declined by an estimated 5% per year while NHL and HPV-associated cancers 
increased by 11.5% and 4% per year, respectively. Concurrently, the overall cancer incidence among 
HIV-negative cases increased by 7.5% per year. Using the population attributable fraction of HIV, 
approximately 45% of cancer among men and 36% of cancer among women was attributable to HIV in 
Botswana. Similarly, Uganda found only a modest decline in KS incidence during the 10 year period of 
ART scale-up: for every 10% increase in ART coverage, KS incidence in the overall general population 
fell by 5% per year. Among the other ADC, cervical cancer incidence did not significantly change and, 
after excluding predominantly pediatric cases of Burkitt’s lymphoma, which is not HIV/AIDS related, the 
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incidence of NHL did not change. Stomach cancer, an infection-related cancer caused by H. pylori, 
declined by 12%. Among virally-associated cancers, liver cancer incidence increased by 12%. Prostate 
cancers, which are two epithelial, non-virally-associated NADC, increased by 5% per year. Together, the 
estimated impact of ART on cancer incidence in Uganda and Botswana was not as robust compared to 
the United States10, 23. For perspective, cancer incidence among the HIV population in the United States 
declined sharply by 29% per year for KS and 16% for NHL during the early HAART era, and subsequently 
by 7.8% and 5.5% those cancers10. Cervical cancer and Hodgkin lymphoma declined consistently by 11% 
and 4% per year. Of note, breast cancer incidence among the HIV population did not change during that 
time in the US10.  
There are several possible explanations for the difference in magnitude between African and 
Western cancer trends in the HIV/AIDS population during the ART era. The first is an issue of the 
denominator used in rate calculations. Analytically, the African studies used the overall population as the 
denominator rather than the HIV population specifically which may have resulted in an attenuation of 
estimated incidence trends compared to the US. Differences in the population used for age and sex 
standardization also prohibit direct comparison of rates between the studies.  Second, the threshold of 
CD4 cell counts was lower (<200 cell/μl) in African settings, resulting in ART initiation at advanced stage 
of disease110. Third, modest declines in the incidence of KS among total cases in Uganda may be partially 
attributable to the high background rate of endemic, HIV-negative KS in the overall population, which 
accounted for up to 10% of total KS prior to the HIV epidemic111, 112. Endemic KS has been described 
geographically as a “KS belt” extending from Cameroon through the Democratic Republic of Congo, and 
through the Rift Valley including Uganda, Tanzania, Malawi and Zambia113. Fourth, at least in the 
Ugandan setting, the lower ART coverage translates to a substantial proportion of the HIV population still 
at high risk for KS; additionally the less frequent use of protease inhibitors during early ART scale-up may 
have resulted in less effective HIV viral control. Fifth, the latency period for cervical cancer is long and it 
remains somewhat uncertain at which points restored immunity from ART is impacting the process of 
HPV-associated carcinogenesis. Low CD4 cell counts are associated with the persistence of HPV, HPV 
viral load and precancerous cervical lesions44 , however partially restored immunity conferred by ART 
may not be sufficient to stop tumor development once a malignant tumor is initiated114. Furthermore, in 
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the Uganda study, high background rates of HIV-negative cervical cancer in the region due to limited 
screening may dilute the true impact of ART scale-up when using incidence rates from the general 
population of HIV-positive and HIV-negative people.   
Record linkage studies have the advantages of characterizing rates using patient level data, and as 
such circumvent ecologic fallacy, overcoming limitations of unknown HIV status among cancer registry 
cases, and explicitly enumerating the denominator of HIV patients at risk for cancer in incidence rate 
calculations. The Uganda AIDS-Cancer Registry Match Study is a population-based study conducted 
prior to the introduction of ART12. More recently, South Africa115, 116 and Nigeria117 have completed HIV-
AIDS cancer match studies during the era of contemporary ART delivery (Table 2-4). Findings affirm high 
ADC incidence rates among the HIV population for KS (Uganda: 240, South Africa: 307 per 100,000 
person-years), cervical cancer (Uganda: 70, South Africa: 447 per 100,000 person-years), and NHL 
(Uganda: 19 per 100,000 person-years, South Africa: not reported). However corresponding excess risk 
of these cancers relative to the general population, presumably uninfected with HIV, was lower compared 
to those observed in Western countries. Incidence rate ratios in these two studies may be attenuated 
towards the null in part due to under ascertainment of cancer cases, and more importantly, due to high 
HIV prevalence in the general population, thereby attenuating results towards the null despite analytic 
corrections. There was no excess risk for liver or penile cancer, virally-associated cancers, despite their 
prevalence in Uganda. High rates of squamous cell carcinoma of the conjunctiva among the HIV 
population were reported in South Africa (men: 58, women: 60 per 100,000), as well as excess risk in 
Uganda (standardized incidence ratio 4.0); together the findings are concordant with early case-control 
reports on this unique association with HIV within the region 118, 119, and later confirmed among persons 
with HIV/AIDS in western countries120 . While still preliminary, Nigerian results show incidence rates and 
excess risk for ADC among the HIV/AIDS population that were lower by orders of magnitude, particularly 
for KS (4.9 per 100,000 person-years), which may possibly be due to low sensitivity of the record linkage 




Table 2-4. Population-level studies of the cancer burden among the HIV/AIDS population and trends 
during ART expansion in sub-Saharan Africa 
Study/Country 
Time Period/ 















Objective: To assess 
impact of ART scale-
up on cancer 
incidence trends 
during 5-year period 
Context: ART 
eligibility was CD4 
<200 cells/μl or WHO 
stage 3/4. ART 
increased from 7.3% 




Registry, with inverse 
probability weighting 
for HIV status  
Methods: ecologic 
study. Trends 
analysis of cancer 
incidence using ART 
coverage (or 
calendar year) as 
ecologic variable in 
Poisson regression   
▪61% of cancer 
occurred among 
HIV+ 
▪45% of cancer 
in men were 
attributable to 
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(95%CI -14.1,  -
2.1) 
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▪Use of IPTW to 
account for the large 
proportion of missing 
HIV status in the 
registry, including a 
sensitivity analysis of 
IPTW estimates 
Limitations: 
▪Cases not receiving 
oncology diagnosis 
and care at referral 




treated with ART 
alone 
▪Consistent with other 
SSA registries routine 
linkage with HIV 
registries is not in 
place 
▪patient level ART 
status, follow-up not 
available 








Objective: To assess 
impact of ART scale-
up on cancer 
incidence trends 
during 10-year study 
period 
 Context: ART 
coverage increased 
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incidence using ART 
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variable in Poisson 
and negative 
binomial models 
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IARC Globocan.   
▪Conducted an 
analysis restricted to 
pathologically 
confirmed cancer 
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▪no change in 
incidence of 
NHL 
▪no change in 
Hodgkin’s, 
cervical, lung or 
colon cancer 
cancer registry may 
be associated with 
null trend 
▪time period may be 
too short to observe a 
change in the 
incidence of cervical 
cancer, which has a 
long latency period 
Record linkage studies 
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estimated from Cox 
regression models, 
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cancer outcomes to 
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▪large contemporary 




▪accuracy of the 
record linkage is not 
known 
▪time-varying CD4 
may not have been 
available from the 























among a sample of 
the HIV/AIDS 
population. Estimate 




the timing of cancer 
incidence across 
early and late incident 
cancers 
Context: pre-ART 





across all stages of 
disease registered in 




(n>15,000).   
Methods: 
Probabilistic record 
linkage used to 
match cancer 
outcomes recorded 
by Kampala cancer 
Registry with HIV 
patients. Cancer 
incidence and 
incidence rate ratios 
were estimated from 
Poisson regression, 
using sex, age, WHO 
stage, category of 
follow-up time 
▪70% of cancers 
were ADC 
▪ Within 2 years 
post-enrollment 
in the HIV/AIDS 
cohort, risk of 
cancer was 
increased 
relative to the 
general 
population for 
KS (SIR 6.4), 











4.0), kidney (SIR 
16), uterus (SIR 
5.5), thyroid 
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covering >90% of 
population in 
Kyadondo county; 
registry is included in 
IARC Globocan.  
▪used KS rates prior to 
the HIV epidemic as 
a comparison in SIRs 
to prevent 
underestimation of 
SIRs caused by high 




ascertainment of KS 
▪does not have follow-
up data, therefore 
assumed 60 months 
follow-up after 
registration, which 
may result in an 
overestimation of 
time at risk for cancer 
Akarolo-Anthony 




4.2% in 2010 




among a sample of 
the HIV/AIDS 
population. Estimate 





coverage; 8.6% HIV 
prevalence in Abuja  
Study population: 
cohort of HIV/AIDS 
patients (n=17,826)   
Methods: 
Probabilistic record 
linkage used to 
match cancer 
outcomes recorded 
by Abuja cancer 
registry (n=2,029) 
with HIV patients. 
Observed cancer 
incidence rates were 
calculated  
▪low rates of KS 
(4.9 per 100,000 
py) and cervical 
cancer (7.8 per 
100,000 py)  
▪low incidence 
rates of NADC: 
liver (1.8), 
breast (1.6) 
ovary (3.6) eye 






increased risk of 
KS (SIR 5.0 
95%CI 4.1, 7.2) 
▪Risk of cervical 
cancer (SIR 2.0, 




relative to the 
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Strengths:  
▪record linkage is a 
robust and efficient 
approach to 
incorporate cancer 





cases by the cancer 
registry 
▪NHL and NADC may 
be difficult to detect 
due to small sample 
size 
▪Incidence rate ratios 
approximating risk, 
may be attenuated 
towards the null due 
to back ground rate of 
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reporting of cancer 
cases: 
▪Registry does not 
collect ADC from ART 
clinics, therefore, it is 
likely that incidence 
rates of KS and 
cervical cancer are 
underestimated, but 
the extent is hard to 
predict  
▪ liver, bladder 
cancers, lymphomas 
are likely 
underreported due to 
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Context: the time 
period covers pre- 
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▪4.5% per year ↑ 
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common cancer 
in men 
▪↑ 3.0% per year 
(95%CI 0.9, 5.1) 
incidence rate of 
cervical cancer  
▪↓ 2.8% per year 
incidence of KS 
in men, but non-
significant ↑1.4% 
(95%CI -0.5, 3.2) 
among women 
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rates of KS and 
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the extent is hard to 
predict  
 liver, bladder cancers, 
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In prior descriptive reports by the Malawi Cancer Registry17 and Uganda Cancer Registry121 KS 
incidence rates remained high since the introduction of HAART. Though treatment coverage and time 
periods analyzed by the registries do differ, 2007-2010 in Malawi and 2002-2006 in Uganda, the findings 
underscore a residual high burden of ADC in the overall population despite ART roll-out initiatives. The 
incidence rate of KS among men in Malawi was 25.4 per 100,000 and 27.9 in Uganda; KS among women 
in Malawi was 11.9 and 20.1 in Uganda. The rate of cervical cancer also remained high: 33.6 in Malawi 
and 38.6 in Uganda, rates that are 3.5 to 4 times higher than in the Unites States82. In Malawi, KS 
incidence increased greater than 2-fold among both men and women between 2000-2003 (pre-ART roll-
out) and 2007-2010, while cervical cancer increased 3.5 fold. The incidence of NHL in Malawi was 2.5, 
one- eighth the rate in the United States, and likely represents an underestimate of the true burden due to 
constraints in laboratory services for this specific cancer diagnosis.  
It is worth mentioning that the methods used in the registry reports were not designed to directly 
assess the impact of ART. An ecologic study using ART coverage over calendar time and analytic 
methods to account for non-linear trends10, 122 would be better suited to address this question specifically 
in Malawi. Furthermore, the increase in incidence rates reported in the Malawi study may be an 
inadvertent artifact of analytically combining multiple geographic areas covered by new surveys during 
2007-2010. A last limitation to interpreting the temporal increase in incidence of ADC in Malawi is that the 
majority of KS is diagnosed in ART clinics, where it is used as a criteria for WHO clinical staging. ART 
clinics are not covered by the Malawi registry’s cancer surveys, only hospitals are, therefore estimates of 
national KS incidence are likely to be underestimated. The 2000-2003 period of pre-ART scale-up is 
probably less subject to under ascertainment of KS since cancer surveillance covered only Blanytyre, 
which housed one of three centers nationwide where ART was available at the time.  With these 
limitations, many questions remain why ADC appear to have increased in Malawi as ART was introduced, 
but due to the aforementioned constraints in healthcare systems, partitioning cancer incidence trends 
among HIV-positive cases has not been possible to date. With this in mind, we propose the Malawi HIV-
Cancer Match Study to more definitively characterize the cancer burden among patients receiving ART.  
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 Overview of the Malawi HIV-Cancer Match Study  
The Malawi HIV-Cancer Record Linkage Study aims to develop an epidemiological resource for 
studying HIV-associated cancer in SSA. The study involves research collaborators and data from the 
Malawi cancer registry and International epidemiologic Databases to Evaluate AIDS (IeDEA) network. We 
will use probabilistic record linkage of ART cohorts and cancer outcomes. Record linkage is versatile tool 
for efficiently merging information across healthcare databases123-125 where it is commonly used to 
supplement routinely collected information on health outcomes, laboratory findings, and risk exposures. 
Our study will be similar to the HIV-AIDS Cancer Match Study22 of the National Cancer Institute in the 
United States, but trends in HIV-associated cancer incidence and patient outcomes in Malawi are likely to 
differ substantially from Western countries.  
Our study will use existing secondary data from the cancer registry and from two ART cohorts in 
Malawi’s largest cities. All patients enrolled at the Queen Elizabeth Central Hospital’s ART clinic in 
Blantyre and the Lighthouse Trust HIV clinic in Lilongwe will be included. The Malawi Cancer Registry is a 
national population-based registry, a founding member of the African Cancer Registry Network, and one 
of only a few cancer registries from sub-Saharan Africa currently included in the WHO Cancer Incidence 
on Five Continents monograph17, 20. Our design incorporates active longitudinal follow-up of HIV-patients 
that will be used to assess risk factors associated with developing cancer following ART enrollment.  
 Summary and public health significance 
The African cancer burden is not static. Over the next 15 years, demographic transitions and the 
adoption of western risk factors will contribute to a doubling of the cancer burden that many countries in 
the region are not adequately prepared to handle. At present, many countries in SSA continue to shoulder 
a high burden of ADC as a result of the HIV epidemic.  
Early initiation of ART and adherence to therapy may afford the opportunity for cancer prevention in 
African countries with high HIV prevalence. Resource rich countries have seen dramatic declines in KS 
since the early days of ART, even in the era prior to HAART. Further epidemiological studies may 
address the question whether such trends could be achieved in SSA where KS continues to be among 
the most common cancers, if not the most common cancer in many countries. Addressing the burden of 
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NADC is also a priority, especially those caused by chronic viral infections, since risk remains elevated 
among the HIV/AIDS population in spite of immune reconstitution conferred by ART.  
Our study will contribute to a more thorough understanding of cancer incidence and incidence trends 
among ART initiators in Malawi, while overcoming limitations from previous studies in the region.  Our 
study circumvents limitations from previous ecologic study designs by using patient-level characteristics, 
including clinical factors, drug regimens, and duration of ART. The HIV cohorts are representative of the 
African context where ART delivery typically occurs at low CD4 thresholds and losses to follow-up are 
non-trivial. The record linkage approach is robust and cost-effective; it is a sustainable health systems 
approach that may be adaptable to other low- and middle-income countries. We will assess the 
performance of this methodology in a resource constrained setting taking into account constraints due to 
missing data and ethnographical considerations specific to Africa. 
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CHAPTER 3. RESEARCH DESIGN AND METHODS 
 Study design 
The Malawi HIV-Cancer Match Study is comprised of 2 observational cohorts of HIV patients 
receiving ART in the central city of Lilongwe and southern city of Blantyre. Cancer outcomes were 
ascertained two ways: as part of the clinical work up for WHO staging during baseline enrollment in the 
ART cohorts, and cross-sectionally through linkage of clinic records with the Malawi Cancer Registry over 
the periods of geographic coverage by the registry (Figure 3-1). 
 
Figure 3-1. Geographic and temporal coverage of cancer by 
the cancer registry in relation to the ART cohorts 
 
 
 Study populations 
ART cohorts  
In Malawi, ART is primarily delivered through public sector hospitals and clinics. Since the 2004 
implementation of free ART to all eligible HIV-infected persons in Malawi, nationwide coverage has grown 
from 3,000 HIV-infected persons receiving ART to greater than a half million in 2014. Currently, 67% of 





Data for this record linkage is derived from two large, well-established ART facilities in the central 
and southern regions of Malawi (Figure 3-1). In the central region, Lighthouse Trust clinic (LT), located 
adjacent to at Kamuzu Central Hospital, Lilongwe is the largest public ART provider. By the end of 2010, 
LT delivered ART to 5,335 HIV-infected persons, of which 3,959 were still alive and on treatment.126 
Queen Elizabeth Central Hospital (QECH) is a tertiary hospital in Blantyre and the largest referral center 
in the Southern Region; by the end of 2010 QECH delivered ART to 7,100 HIV-infected persons (Table 3-
1). QECH began as a fee-for service clinic in 2000 and since 2004 has provided free ART under the 
Ministry of Health ART scale-up plan.127  
 
Table 3-1. Coverage of ART initiators by city and region 
ART clinic City, Region 
Number of patients 
receiving ART in 2010  
2015:  Number of new ART 
initiators, coverage of ART 
initiators  
Lighthouse Trust (LT) Lilongwe, 
Central 
5,335 N=5,360 
36% of new initiators in Lilongwe  








10% of new initiators in Blantyre, 
2% of al initiators in Southern 
region 
Source: Malawi Ministry of Health Q1 2015 report 
 
 
LT and QECH use an electronic data system to routinely collect demographics, baseline and follow-
up clinical data (WHO stage, HIV viral load, CD4 count), and ART information since January 2005 and 
2008, respectively.126, 127 Historical records of ART initiators were retroactively validated and added to the 
electronic data system.  
Active tracing is used for patient follow-up and ascertainment of vital status. Confirmatory HIV 
diagnosis and WHO clinical staging are provided at time of entry into care. WHO stages, categorized as 1 
through 4, are defined by specific clinical conditions or symptoms. The staging scheme is practical for 
managing patients in low-income settings with limited laboratory capacity; studies in Africa show strong 
correlation between WHO staging and CD4 count and total lymphocyte count.128-131 In Malawi, historically, 
CD4 counts were restricted to clinical stages 1 and 2 patients who were not clinically eligible for ART, and 
among these patients, timing of laboratory assays was not uniformly proximal to start of therapy. For 
QECH prior to 2011, CD4 counts were not captured in the electronic monitoring system and therefore 
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were not available for analysis. Beginning in 2011, new guidelines were instituted for routinely monitoring 
HIV RNA in all patients at 6 months, 1 year, and 2 year intervals. Extensive data for CD4 counts and HIV 
RNA were therefore not available during the time period of our study reflecting practice within the Malawi 
national HIV program. 
Malawi cancer registry  
The Malawi cancer registry is a founding member of the African Cancer Registry Network 
(http://afcrn.org/index.php), which provides training in population-based cancer registration, technical 
support, and coordination of international research projects. The cancer registry began as a pathology-
based cancer registry at QECH in Blantyre in 1985, and subsequently expanded to a national cancer 
registry in 1989.17, 132 In 1993, population-based activities for the Blantyre District were expanded. Active 
case-finding is conducted through cross-sectional surveys of secondary (district-level), tertiary (central-
level), and major departments of other public and private hospitals. Sources of information include 
outpatient departments, inpatient wards, clinics, laboratory, pharmacy, surgery, and mortuaries. 
Population-based cancer registration was expanded over a catchment area of urban and rural Blantyre 
during 2001, 2003, and 2005 surveys. Select neighboring districts were also surveyed though case-
ascertainment was less complete than in Blantyre.  In 2010, a nation-wide population-based survey 
covering 2007-2010 diagnoses was conducted at 81 out of 84 hospitals. Three international facilities 
declined participation in the 2010 survey; their population catchment areas are not known.  
Cancer diagnoses are collected using the IARC standard procedure manual for cancer registration in 
SSA. Data are coded using the International Classification of Disease for Oncology (ICD-O).133 
Information on diagnosis and treatment are processed and stored in WHO cancer registry software 
CanReg4 which checks for duplicates, reviews implausible combinations of codes, and calculates age-
standardized incidence rates.134 Stage of disease is generally limited in the registry as a direct result of 
limited diagnostic capacity in many hospitals. Systematic vital statistics, including death certificates, are 
not available and therefore not routinely used as a source of information in the cancer registry. Incidence 
rate calculations rely on population projections covering 1999-2012 from the National Statistical Office of 
Malawi (http://www.nsomalawi.mw/). Registry operations are approved by the Malawi National Health 
Sciences Research and Ethics Committee (NHSRC). 
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Inclusion and exclusion criteria for record linkage  
Additional years of data for QECH and cancer registry datasets were made available to the analytic 
team. Incorporating the additional years of data does not statistically harm the linkage, therefore all data 
was deemed eligible for linkage under the assumption that the final analytic set would be trimmed to 
reflect temporal and geographical overlap between coverage of cancer registry diagnoses and ART 
cohorts. No restriction on age or cancer type was placed on the record linkage.  
All patients enrolled at QECH from January 1, 2000 – October, 1 2015 were eligible regardless of 
prior cancer diagnosis or length of patient follow-up (N=23,743). Similarly, all patients enrolled at LT from 
January 1, 2007 – October 1, 2010 were eligible (N=26,977). The entire dataset for the cancer registry 
from 1985-2010 was used for the record linkage (N=62,944). Among cases with missing district of 
residence, the district hospital where the case was recorded was used as a proxy for residence, except 
for cases collected from Kamuzu Central Hospital (Lilongwe), Zomba Central Hospital, or Queen 
Elizabeth Central Hospital (Blantyre) which are large oncology referral centers with catchment areas 
spanning the most of the central and southern regions, respectively. 
 Background on probabilistic record linkage  
Overview  
Our goal is to merge cancer outcomes to two observational cohorts of patients receiving ART in 
Malawi. Because the datasets are large, conducting a manual linkage of records was unfeasible. We 
considered two main approaches: deterministic and probabilistic methods for linking the datasets 
together. Deterministic linkage groups records using unique or non-unique identifiers, such as names and 
birth dates, and relies on the exact match of one or more identifiers. Probabilistic linkage also groups 
records using non-unique identifiers, but instead uses the probability of matching across a set of variables 
for a given record pair. 
Probabilistic methods overcome the setbacks of strict deterministic linkage. In the real world, data 
entry errors and changes in patient demographics may arise in patient records: changes in civil status 
and last name, change in residence over time, the use of nicknames and aliases, and data entry errors 
from handwritten notes. Such errors and changes lead to the failure of deterministic methods which rely 
on exact matches. In contrast, probabilistic methods handle minor discrepancies across the linkage 
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variables. A match probability and weight is calculated for each potential record pair across each linkage 
variable. The match weight is the likelihood that two records truly match given agreement on a set of 
patient identifiers. A high weight indicates a high degree of similarity between a record pair, and a low 
weight indicates dissimilarity.  Record pairs are then classified by their weights into one of 3 categories 
using a process known as highest-weight classification, resulting in three outcomes: definite match, 
possible match requiring review, and non-match. Records with the highest weights above a 
predetermined weight threshold are categorized as definite matches, while potential matches require 
review.  
Linkage variables  
Ideally, a combination of unique identifiers (e.g. Malawi health passport numbers, cell phone 
numbers) and non-unique identifiers (names, birth dates) are typically used for linking a master dataset 
with another file. In our study, unique identifiers such as Malawi health passport numbers were not 
available in the study datasets, therefore we used a set of 5 demographic variables for linking the 
datasets together: first name, last name, year of birth, sex, and district of residence. The chosen variables 
are shared across data sources.  
Linkage methods overview  
The objective is to match pairs of records across datasets through a process of assessing patterns of 
agreement across the set of linkage variables. The end goal is to produce a final summary score for each 
record pair separately by considering agreements across the set of 5 linkage variables.  
Under the simplest scenario, a pair of records may have exact agreement or disagreement on a 
given linkage variable. For example, a binary variable sex coded as 0 for male and 1 for female will have 
only an exact agreement or disagreement. Under a more complex scenario, we also allow for partial 
agreement across a text field such as name, or numeric field such as year of birth. Partial agreement 
allows for small discrepancies in text fields. Missing values on a given linkage variable are not scored, 





Definitions of m and u conditional probabilities  
Probabilistic record linkage relies on Bayes’ theorem.135, 136 Two conditional probabilities are the 
basis for constructing a summary weight for each record pair. In the literature of record linkage these 
probabilities are commonly referred to as m probability, also known as match probability, and u 
probability, also known as unmatch probability.   
The m probability is the conditional probability of a match on a linkage variable given that two 
records truly do belong to the same person:  
m =  p (match on link variable | True Record Pair) 
Using the linkage variable first name as an example, an m probability of 0.9 is interpreted as the 
probability that any given pair of records truly belonging to the same person will agree on first name 90% 
of the time. The 0.1 discrepancy is attributed to data quality issues such as misspelling (MarieJo versus 
MaryJoe), data entry error (MarieJo versus MarieJane), missing data (.), or a possible actual name 
change (MarieJo versus Jo).    
The u probability is the probability of a match on a linkage variable given that two records do not 
belong to the same person or, randomly matching by chance: 
u =  p (match on link variable | True non-Pair) 
The u probability depends on the distribution of values for a given linkage variable in the dataset. For 
example, for the variable sex, one could specify a probability u=0.5 or use the observed distribution of sex 
from study data. In Lighthouse Trust, the u probability for men is 0.422 and 0.578 for women. Similarly, 
for the linkage variable last name, each unique name has a u probability which is specific to the study and 
local context, such as geography. In the Lighthouse Trust, located in central Malawi, the u probability for 
last name ‘Banda’ is 0.0419 and 0.038 for ‘Phiri’. At Queen Elizabeth Central Hospital, located in the 
southern region, the u probability for ‘Banda’ is 0.0218 and 0.018 for ‘Phiri’.  
More intuitively for epidemiologists, m and u may be conceptualized through a 2-by-2 table of record 
match status from linkage algorithms compared to the true match status measured from a hypothetical 
gold standard dataset (Table 3-2).  Here, the m probability is analogous to sensitivity, while the u 
probability is analogous to 1-specificity:   
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m =  p (match on link variable | True Record Pair) 
m or sensitivity = True Match / (True Match+ False non-Match) 
u =  p (match on link variable | True non-Pair) 
u or 1-specificity  = False Match / (False Match+ True non-Match) 
 





                 Truth (unobserved) 
Records belong to 
the same person 
(True Record Pair)  
Records do not belong to 
the same person (True 
Non-Pair) 
 
HIV clinic record 







HIV clinic record 










Likelihood ratios.  The overarching goal of constructing linkage weights is to assess the 
performance of the match algorithms in identifying true cancer cases. The goal may be viewed as 
analogous to the process of measuring validity of clinical diagnostic testing. In diagnostic testing, the 
likelihood ratio for a positive test is the ratio of the probability a correct result to the probability of an 





The likelihood ratio used to assess a positive result from matching algorithms on a given variable is 
therefore:  m / u. In our study, the likelihood ratios were logarithmically transformed to handle skewness.    
Constructing the weights using Bayes’ Theorem.  For epidemiologists, the process of 
constructing linkage weights may also be understood by working through Bayes’ theorem. Using a simple 
notation for Bayes’ theorem, event B is the event that two records truly belong to the same person and 
p(B) is the probability of the event. The complement event B̅ is the event that two records truly do not 
belong to the same person, and  p(B̅) is the probability of the event. 
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A1 through A5 are the events of matching values on each of the 5 linkage variables first name (A1), 
last name (A2), year of birth (A3), sex (A4), residence (A5), and p(A1) through p(A5) are the probabilities 
of the corresponding events A1 through A5.  Applying this notation to the m and u probabilistic described 
in the section above: 
m =  p (match on link variable | True Record Pair) = p (A1| B) 
          u =  p (match on link variable | True non-Pair)= p (A1| B̅) 
 
 
Recalling our goal to obtain a likelihood ratio for a positive match on a set of identifiers, the 
conditional probabilities of a true record pair given agreement on variable A1 and the conditional 
probabilities of a true non-pair given agreement on variable A1 are: 
p (B|A1 ) = 
p(A|B )·p(B)
p(A )




Manipulating the above probabilities to obtain the odds of getting a true record pair to a true non-
record pair when we match on A1 provides the epidemiological terms posterior odds, likelihood ratio, and 
prior odds138 : 
p(B|A1 )
p( B̅|A1)
  = 
p(A1|B )
p(A1| B̅ )





     posterior odds        likelihood ratio    prior odds  
     of a true pair           m / u                  of a true record pair 
     given agreement 
     on variable A1  
 
 
A major assumption used a probabilistic linkage approach is conditional independence of events 
across the set of 5 linkage variables. For example, we may assume that two records matching on first 
name is independent of the same two records matching on year of birth given the records truly belong to 
the same person. We assume that events A1 and A2, A1 and A3, A1 and A4 and so forth, are 
























The final step is logarithmically transforming all terms so that posterior log odds of a true record pair, 
given agreement across A1 through A5 variables, is the sum of the log likelihood ratios for each variable 


























In our study, we assume that the prior probability of a match is small, and consequently the prior 
odds will also be small. We expected that a small proportion of all HIV patients in the cohort will develop 
cancer; we did not expect a 1:1 match of HIV records to the cancer registry.  
Record classification  
Finally, highest-weight classification is used to classify record pairs into matches, non-matches, and 
potential matches requiring further adjudication. The weight thresholds used during the classification 
process are specific both to the data at hand and the purpose of the research. Record linkages are 
typically run iteratively to refine weight thresholds.136 Our study team decided on the weight thresholds 
after manually reviewing data quality of the record matches and the range of weights observed in our 
study. We choose weights equal to or greater than 23 as definite matches, and weights between 12 and 
23 as potential matches. A weight less than 23 in our study is the point at which data quality issues or 
missing data introduce uncertainty, and extra clinical information from the HIV medical record or the 
cancer registry is required to make a final determination.   
Outcome misclassification in probabilistic record linkage  
Inherent in any probabilistic method is a degree of uncertainty in the match versus non-match 
outcome 139, 140, a problem we will refer to as measurement error. Excessive missing data and lack of 
discriminatory power among patient identifiers may cause linkage errors that result in false positive 
matches (records that link erroneously) and false negative matches (records that fail to link).18, 19 
 
38 
Subsequent analysis should take these errors into account, but this seldom reported.140 Even small errors 
can introduce substantial bias141, as seen in a Swiss study where missed linkages caused an 
underestimation of mortality rates.142 
There are three challenges driving outcome measurement error in probabilistic record linkages. The 
first is measurement error on match variables, which can be viewed analogously as “exposure variables”. 
These errors are language and context specific. For example in Malawi, certain letters like ‘r’ and ‘l’ are 
commonly interchanged in Chichewa, the local Bantu-based language. Additional discrepancies may 
arise from typographical errors occurring during data entry, and variations in patient demographics, and 
the use of nicknames. Probabilistic methods are well-suited to handle minor discrepancies such as these 
across match variables of interest.136, 143 Second, common surnames and first names present a major 
challenge because they limit the discriminatory power of linkage on name. For example, the two 
surnames “Banda” and “Phiri” account for nearly 7% of names in our study population therefore matching 
on a common surname for these records contributes little to the total summary weight for those records. 
In contrast, rare names contribute a high weight towards the overall summary weight of the record pair. 
Common first names and use of aliases during hospital registration also lower the discriminatory power of 
name as a matching variable. Changes in civil status and surname, and changes in place of residence 
over time are also problematic for the linkage process since the analyst cannot know a priori which record 
is ‘correct’. Legitimate variations in these demographics are marked as discordances during the match 
process which in turn lowers the summary match weights for the affected record pairs. Assuming that 
these record pairs make the cutoff as potential matches, they are clerically reviewed and resolved using 
additional information from the electronic medical records.   
Missing data on match variables is third challenge in using real-world data from a resource-limited 
environment: fully-complete identifiers including name, date of birth and residence, are available for only 
a subset of all records. Country-specific circumstances such as lack of vital statistics cause substantial 
missing data on date of birth. Compounding the problem are healthcare interviewing techniques which 
introduce further measurement error in date of birth: older patients who do not know their date of birth 
may be interviewed by healthcare workers using well-known historical events to determine the 
approximate age if the patient, or worse yet, healthcare workers may estimate age based on physical 
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appearance. Taken together, measurement error and missing data in match variables may substantially 
lower summary linkage weights, creating a situation of high uncertainty in the ‘true’ match status of 
records.  
Several approaches can be used to quantify uncertainty and reduce bias in record linkage studies 
140: i) conduct clerical review of all potential matches, the number of which may be prohibitive in terms of 
time and cost; ii) conduct validation and evaluation of linkage performance using a gold-standard dataset 
144 , if such a dataset exists, and adjust weight thresholds accordingly; iii) employ analytic approaches to 
incorporate uncertainty into post-linkage analyses, such as Bayesian prior-informed multiple imputation of 
match weights.18, 145, 146   
 Specific Aim 1 
Specific Aim 1. Adapt, implement, and evaluate a probabilistic linkage methodology suited to health 
systems in a resource-limited setting.     
Since shared unique identifiers are not available across datasets, a probabilistic approach was used 
as a first pass approach to identify sets of definite and potential matches. Though ART cohorts and the 
cancer registry have unique patient ID numbers, a cross-walk between the two does not exist, nor does 
Malawi use a national ID analogous to a Social Security Number.  Given the large number of potential 
matches that contained missing data, a second pass, labor-intensive approach of manual linkage, 
followed by clinical review was used to further assign potential matches into definite matches or non-
matches. LT and QECH were linked to the cancer registry separately. The study workflow describing 
each step is summarized in Table 3-3. 
Data preprocessing and probabilistic record linkage were performed in KNIME Analytics Platform 
Version 2.12.1 (Konstanz, Germany)147, an open-platform data miner, utilizing the K-Link probabilistic 
linkage plug-in. Data pre- and post-processing were conducted in STATA 14 (Stata Corporation, College 
Station, Texas) and SAS 9.4 (Cary, North Carolina). Personal identifiers were made available to the 
linkage analytic team (Horner, Spoёrri, Chasimpha). All data were encrypted using TrueCrypt 7.2 on 
portable drives and BitLocker on Windows 8.1 laptops.    
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Table 3-3. Summary of workflow in probabilistic record linkage 
Step Description 
Evaluate and 
choose the set of  
linkage variables  
Evaluate the proportion of missing data across potential linkage variables, 
choose a set of variables that are consistently recorded across datasets to serve 
as the basis for matching  
Pre-Processing Data harmonization, formatting, correcting errors, de-duplication of datasets, 
removing non-essential variables from datasets 
Blocking Define selection criteria, blocking, reduce the number of record pairs for  
comparison  
Define rules for 
each linkage 
variable  
Define weights for each variable, rules for margin of error (e.g. date of cancer 
diagnosis +/- 5 years of ART initiation) 
Define u and m 
probabilities 
Conditional probabilities of a record pair being a match or non-match are derived 
using the study data 
Run probabilistic  
linkage 
Pre-processed datasets are run through KLINK 
Refine weight 
thresholds  
Go through the iterative process of re-running the linkage algorithms to evaluate 
the performance of linkage weight thresholds; categorize matches and non-
matches, assign potential matches for deterministic linkage and clinical review  
Construct manual  
deterministic 
linkage 
Logic rules parse potential matches based on dates, residence, and facility 
where cancer diagnosis occurred (e.g., date of cancer diagnosis< date of death; 
cancer diagnosis at district hospital used as a proxy for district of residence 
when it is missing); deterministic linkage is used to review nicknames and full 
date of birth when available  
Conduct clinical 
review of potential 
match pairs 
Review of potential cases by 3 Malawian senior clinical investigators (Drs. 
Dzamalala, Malisita, Masomba) using additional clinical information (e.g. cancer 
stage and subsequent treatment, age at cancer diagnosis compatible with HIV 
clinical history)  
Post-processing Relink clinical variables of interest for analysis, remove personal identifiers, 
create a master linkage key  
*All data were encrypted during the record linkage process. Final datasets contain only anonymized data. 
 
 
The set of linkage variables used for matching were last name, first name, year of birth, sex, and 
district of residence as these were common identifiers across datasets. Place of residence was recorded 
as free text in the ART datasets but was determined to be unusable as a linkage variable given the lack of 
physical street addresses; further, the cancer dataset only documented residence at the district level. 
Therefore, district was used as the geographic unit of interest for record linkage. Consistent with other 
African research settings, date of birth was estimated for a substantial proportion of records. Therefore, 
only the year of birth was used as a linkage variable, allowing for 5-year discrepancies between record 
pairs during subsequent iterations of the linkage.     
Data pre-processing is the most time-consuming and labor intensive step of a data linkage.  
Sophisticated software packages and algorithms cannot correct for poor quality baseline data during the 
linkage. Therefore the success of record linkage is highly dependent on quality data. Pre-processing 
 
41 
involves de-duplicating records, standardizing formats for variables such as dates, and correcting 
miscoded or missing data. Patient records were consolidated when more than one observation was 
present per individual. Variables that were not directly used for record linkage were temporarily removed 
from the datasets.  
Data was pre-processed to harmonize variables across datasets. Greater than 4000 distinct, free-
text patient residences were recoded to the district level in each ART cohort master file. In the cancer 
registry, hospital facility was used as a proxy for the district of residence when these were missing, except 
if the hospital was one of three major referral centers: Kamuzu Central Hospital, Zomba Central Hospital, 
or Queen Elizabeth Central Hospital. Cancer patients are often diagnosed at the district hospital closest 
to their residence, prior to receiving referral for oncology services in Lilongwe or Blantyre. After assigning 
the proxy residence, x% of cancer cases still had missing district of residence.  
Regular expressions were used for name parsing and removing prefixes, titles, salutations, special 
characters and handling initials. In computer science, regular expressions form the basis of search 
patterns for text strings; these were specifically configured to our study using Espresso 2.1 regular 
expression editor, then written into the KNIME Analytics data miner147.   
Pre-processing is context and language specific. Beyond issues surrounding name changes due to 
marriage, maiden names, and nicknames, a particular consideration in the Malawian context is the 
variation in the spelling of names. Certain letters are used interchangeably such a ‘r’ and ‘l’, ‘y’ and ‘ee’, 
among many others. A consensus on spelling variations and nicknames for >8000 Malawian common first 
and last was established by local data staff from Tidziwe Center, Lilongwe (Salima, Chilima, Mukatipa) for 
use in subsequent steps of review and deterministic linkage. Also, context specific is the use of 
salutations that are recorded as part of the patient name in Malawi.  Salutations need to be removed from 
name fields during pre-processing. The challenge is balancing the true variation in name spellings that 
allows algorithms to discriminate between records and excessive data cleaning.  
Blocking was used to define potential pairs. Blocking is also referred to as selection criteria ‘pockets’ 
or stratification of record comparisons according to a given value (see example). Comparisons are 
restricted to records in the same block, for example records with the same birth year. Blocking is a means 
to managing the unwieldy number of record comparisons that would otherwise occur during linkage. The 
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number of record comparisons is the product of the number of records in each file: N1*N2. Given that the 
LT dataset has N1 >23,000 records and the cancer registry dataset has N2 > 60,000 records, the product 
easily exceeds 1,380,000,000 comparisons of potential pairs, which is computationally unfeasible in the 
absence of a blocking step. The goal therefore is to quickly reduce the number of potential pairs by 
throwing out pairs with no match in a given block, while allowing for some flexibility of error in the 
variables. In other words, the goal is to find the potential pairs that are worth looking at. Records pairs 
with low weights are unlikely to be matches, while those with high weights are more likely to be matches.   
 
Example of Pockets 
Pocket 1  Match on year of birth 
OR 
Pocket 2  Match on sex AND residence 
OR  
Packet 3  Match on last name AND year of birth 
OR 
Pocket 4  Match on first name AND year of birth 
 
Linkage rules are then defined for each potential pair across each variable, depending on whether 
the variable is a date, string or numeric: agreement, disagreement, or missing if one or both records are 
missing information on a given variable. Partial agreements are possible depending on the a priori set of 
matching rules defined by the analytic team. Again, rules for partial agreements are context specific. In 
Malawi, where dates of birth are often not exact or are missing one or more fields of day, month, and 
year, we created a rule allowing for a 5- year margin of error in the year of birth, an approach that has 
been applied in other healthcare linkage studies in Uganda and South Africa. Partial agreements are 




Example of rules for names in Malawi.  
* indicates the approach used in the HIV-Cancer Match Study 
 
Rule 1     *Total agreement  
Rule 2     Typographical errors: transposition (mary to mayr),  
character mismatch (mary to mari), extra characters (mary to marry) 
Rule 3     *Aliases: nicknames (beth, liz, lizzy for elizabeth), used during the second phase 
deterministic linkage 
Rule 4     *Similarity comparison of n-grams. Other strategies include comparing text strings 




Linkage -m and u-probabilities are iteratively derived using the study data (Figure 3-2). The u-
probability is the probability of getting a match on linkage variable given that two records truly do not 
belong to the same person, or matching by chance. The u-probability depends on the distribution of a 
given linkage variable in the dataset. For example, for the variable sex, one could specify probability 
u=0.5 or adjust it to the observed underlying frequency distribution of sex in the study population; our 
study did the latter.  
 
Figure 3-2. Iterative linkage process for generating m and u probabilities 
 
 
After running the first round of linkage, the next step is to refine weights, set the classification 
thresholds, and categorize the records pairs in one of the three groups: match, non-match, and potential 
match. In the initial iterations of running the linkage, record pairs are quantitatively reviewed across each 
variable’s weight and total weight using histograms and descriptive statistics. Qualitative assessment 
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considers overall characteristics of the data such as the frequency of common last names, the proportion 
of missing data for district and misclassification of year of birth driving the distribution of weights for those 
respective linkage variables. Linkage rules are then fine-tuned to reflect the importance of each variable 
in predicting a match within our specific data. The linkage is re-run with the new specifications. Total 
weight thresholds are defined after an iteration of manual review of a sample of linked record pairs.  
Deterministic review of records falling in the category of potential matches was the second stage of 
record linkage in our study. Often the potential matches had missing data, which drives down the overall 
total weight for the record pair. Names, year of birth and district were manually reviewed for record pairs 
that had the lowest weights. The directory of common name variations and nicknames was consulted 
during this review. Logic rules were constructed to further assign potential matches into one of two 
categories: those requiring clinical review and non-matches. The following logic rules were applied: 
 
Rule during manual review Record-pair 
outcome 
Date of death recorded in ART cohort < date of cancer diagnosis non-match 
Date of cancer diagnosis< date of birth non-match 
Not enough information to assign outcome due to missing date of cancer 
diagnosis  
non-match 
Not enough information to assign outcome due to missing year of birth and 
low linkage weight and year of cancer diagnosis occurs >5 years before ART 
cohort enrollment 
non-match 
District of residence is missing, but the location of cancer diagnosis is within 
proximity to the ART clinic, therefore the potential match meets the “physical 
presence test” of being present in Lilongwe or Blantyre to receive healthcare 
services  
requires further 
clinical review  
 
 
Clinical review was conducted by 3 senior Malawian investigators using additional oncology 
treatment data collected by the cancer registry. Patient identifiers were made available to the reviewers in 
order to also consult the register of the External Referral Committee, which documents patients 
sponsored to receive oncology care abroad. Potential matches that linked with a cancer diagnosis 
occurring more than 5 years prior to ART cohort enrollment (LT n=105; QECH n=163) were reviewed for 
biologic and clinical plausibility according to the criteria below (see table). Reviewers were provided with 
1) information pertaining to the cancer diagnosis: date of diagnosis, age at diagnosis, cancer type, cancer 
histology, tumor behavior, basis of diagnosis, facility where data was abstracted, treatment, sex; and 2) 
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information pertaining to the ART cohort: age at ART enrollment, ART facility, cancer diagnosis recorded 
by ART facility (if any: KS or cervical cancer), time between registry cancer diagnosis and ART 
enrollment, last date of patient contact, patient outcome as of last date of contact. The final match 
outcome after clinical review were categorized as match, non-match, and equivocal. Equivocal 
conclusions were recoded as non-matches in the final analytic dataset.  
 
Criteria during clinical review 
Review Criteria #1: Is age at cancer diagnosis compatible with the data presented? (yes, no, 
equivocal) 
Review Criteria #2: Is the treatment information and diagnosis date compatible with survival time 
between the cancer diagnosis and ART enrollment? (yes, no, equivocal)             
Review Criteria #3: Consider if the case was referred out of country by reviewing the register from the 
External Referral Committee. Is the clinical data compatible with criteria 1 and 2? (yes/no/not 
applicable) 
Final conclusion: enter the final review conclusion. (1=match; 0=clinical data not compatible with a 
match; equivocal).  
 
During post-processing, clinical information from ART was merged with the final linked analytic file. 
All personal identifiers were removed to protect patient confidentiality. An encrypted linkage master key 
containing a matrix of linked IDs and patient names is maintained by the in-country analysis team 
(Horner, Chasimpha) to allow for record linkage updates in the future. 
Statistical analysis specific aim 1.1  
Since LT and QECH were independently linked to the cancer registry, the u- and m-probabilities and 
subsequent linkage weights are specific to those cohorts. Therefore, all analyses in Specific Aim 1 were 
conducted separately for each cohort. 
Analyses used the final linkage weight cut-point  as the basis for classifying potential matches (12 
<weight score <23) and definite matches (weight score ≥23). Potential matches were adjudicated in 
subsequent steps of manual review. 
First, the overall proportion of matched and potentially matched records at each stage of the linkage 
process was graphically presented as a flowchart for each cohort separately. To illustrate potential bias in 
the classification of match outcomes due to missing data, the proportion of missing values for each 
linkage variable were presented for definite and potential matches.  For each variable, we presented two-
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by-two tables showing a) the number and proportion of discrepancies and perfect matches among definite 
and potential matches, b) the number and proportion of missing data among definite and potential 
matches. Among 2x2 tables for a), we described the proportion of definite matches that had partial 
agreement t on first and last name as compared to an exact match on name.  Chi-square test were 
calculated to assess differences in the proportions of a) imperfect matches and b) missingness on high 
weight and medium weight linkage outcomes. 
Lastly, to illustrate how the local distribution of names impacts our linkage study, we compared 
scatter plots of frequency distributions for first and last names by the linkage weights for these respective 
variables, stratified by imperfect and perfect matches on name. The goal was to illustrate that in a 
population with very common last names, even perfect record matching will have only modest linkage 
weights that require manual review.  
 Specific Aim 2 
Specific Aim 2. Characterize cancer incidence rates and clinical timing of cancer diagnosis among 
ART initiators in Malawi, while accounting for outcome measurement error in a methodologically rigorous 
way.  
Inclusion and exclusion criteria for analytic dataset  
Patients newly enrolled on ART in the QECH cohort with a first clinic date occurring between 
January 1, 2000 and August 31, 2010 were included in the analytic dataset, regardless of prior or current 
cancer diagnoses.  Similarly, patients newly enrolled on ART in the LT cohort with a first clinic date 
occurring between January 1, 2007 and August 31, 2010 were included for analysis.  
Patients enrolled on ART for a single day were excluded as these represent patients who received 
emergency pharmacy refills. The temporary transfer of these patients into care at LT or QECH was 
verified against the mastercard for transfer-ins, which is electronically entered into the ART facility 
database and was made available to the analytic team. Patients enrolled in care at LT or QECH only for 
receipt of chemotherapy for KS were excluded; these patients receive ART at a separate facility, such as 




Incidence will be restricted to the first cancer primary recorded by the cancer registry. Multiple cancer 
diagnoses occurring within 90 days of the first diagnosis were considered to be part of the clinical work-up 
of a single event. Subsequent multiple primaries occurring more than 90 days after the first primary were 
excluded to avoid misclassification with cancer metastases. Cancer diagnoses that were linked beyond 
the last date of contact or 180 days past the default date were excluded from primary analyses.  
Prevalent cancers are defined as those that were clinically ascertained within the first 90 days of 
ART enrollment or that occurred prior to enrollment. Early incident cancers are defined as those occurring 
between 4-24 months days after ART enrollment; late incident occurring greater than 24 months after 
ART enrollment.  
Person-time definition  
Person-time on ART was calculated from 90 days after ART enrollment into the cohort until a cancer 
event, ART cessation, clinic transfer, default or death. Among defaulters, also known as lost to follow-up, 
the ART outcome date recorded in the electronic medical record (EMR) is the default date. Person-time 
among patients who defaulted, or lost to follow-up, was defined as the date of the date of the last 
scheduled appoint or prescription refill that was missed. Calculations of person-time at risk among 
defaulters included a 180- day window of active tracing past the missed appointment date (Figure 3-3).  
Covariates  
Clinical and demographic characteristics were considered as covariates for Poisson regression rates 
(Table 3-4). 
 
Table 3-4. Covariates 
Variable Description Values 
WHO stage Categorical 1 or 2, 3 , 4 
Reason for ART initiation Categorical CD4 level, Pregnant, Breastfeeding, Presumed severe 
HIV infection in infant,  WHO stages 1 or 2, WHO stage 
3, WHO stage 4 
Age group Categorical 0-14, 15-29, 30-39, 40-49, 50-59, 60-69, 70+ years 
Sex Binary  Female, Male 









Descriptive analysis of LT and QECH study populations compared patient characteristics across the 
periods 2000-2003 (pre-ART), 2004-2007(early ART scale-up), 2008-2010 (late ART scale-up). The 
distribution of cancer diagnoses according to clinic cohort, 5- year age group, sex, method of cancer 
diagnosis, site-specific cancers, category of cancer diagnosis (prevalent, early incident, late incident); 
person-time between ART enrollment and cancer diagnosis, and  ART person-years were described.  
Statistical analysis specific aim 2 
In primary analysis, incident and prevalent cancer diagnoses will be defined relative to the date of 
ART enrollment.  
Cancer incidence rates were calculated per 100,000 person-years and corresponding 95% 
confidence intervals (95% CI) among persons receiving ART for all sites combined and site-specific 
cancers. Incidence rates were presented by category of early (4-24 months post enrollment) and late 
cancer incidence (>24 months post enrollment). 
Poisson regression was used for estimating cancer counts and rates by clinical and demographic 
covariates. People with prevalent cancers were excluded from the population at risk. We applied direct 
standardization for age (0-15, 16-25, 25-35, 36-45, 46-55, 56+ years) and sex (male, female) using 
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population weights derived from LT and QECH cohorts combined; otherwise we used sex-specific age-
adjustment for male and female populations, respectively. 
 Sensitivity analysis 
To quantify the impact of linkage misclassification on cancer incidence rates, we will conduct a 
sensitivity analysis using probabilistic methods alone compared to the second-pass linkage that uses 
extensive adjudication of records.  
Further sensitivity analyses explored incidence rates among persons with prior ART exposure, who 
transferred into care at LT or QECH from another clinic. We consider a sensitivity analysis using the 
interval of unobserved person-time among this sub-cohort of patients with a documented date of prior 
ART exposure (Figure 3-4).  
 









Table 3-5. Definitions of ART person-time, cancer outcomes, and limitations of each analytic approach in Specific Aim 2 
Person-time calculation Outcome classification Limitations 
Primary analysis 
▪Person-time using only observed ART person-
time occurring among new ART users  
▪Person-time start date=date of ART cohort 
enrollment 
▪Person-time end date=date of last contact if 
dead or alive, or 180-days past date of last 
contact if defaulted or lost to follow-up 
 
▪Prevalent cancers=diagnosed prior to 
cohort enrollment or within first 3 months of 
enrollment 
▪Early incident cancers=diagnosed 4-24 
months post-enrollment 
▪Late incident cancers=diagnoses 
>24months post-enrollment  
 
Restriction to subset of cohort deduces 
sample size  
Sensitivity analysis: unobserved prior ART exposure 
▪Person-time using unobserved ART person-
years + observed ART person-years among 
the sub-cohort of prior ART users who were 
referred to LH or QECH 
▪Person-time start date=date of ART 
▪Person-time end date=last date of contact if 
dead or alive; 180 days past date of last 
contact if defaulted or lost to follow-up 
 
▪Prevalent cancers=diagnosed prior to 
recorded ART initiation or within first 3 
months of initiation 
▪Early incident cancers=diagnosed 4-24 
months after ART initiation 
▪Late incident cancers=diagnoses 
>24months after ART initiation 
 
Limitations of unobserved person-time: 
1.ART adherence is unobserved. It is 
unknown if the patient defaulted during 
the time they initiated ART and 
subsequently enrolled in the cohort 
2.WHO stage at ART initiation is 
unknown, but may be assumed based on 
guidelines at the time 




CHAPTER 4. OPPORTUNITIES AND BARRIERS TO BIG DATA APPROACHES IN GLOBAL 
HEALTH: A CASE-STUDY OF HIV-CANCER RECORD LINKAGE IN MALAWI 
A. Introduction  
Big data approaches provide exciting opportunities to improve population health in low- and middle-
income countries.148  Countries in Africa are no exception and are currently experiencing a data 
revolution.149, 150 In this context, novel analytical approaches to integrate data from diverse sources can 
help fill critical knowledge gaps with respect to clinical care and population health. For example, data 
linkages of electronic medical records from healthcare systems and traditional sources of disease 
surveillance data, such as registries, have potential to bridge infectious disease and non-communicable 
disease research silos in Africa.151  
Big data broadly refers to four dimensions of data. Volume reflects the size of the data; velocity, the 
rate at which is it produced; variety, the complexity of sources and formats; and veracity, the certainty of 
the data.152 New analytical methods, such as machine learning, increased computing power, and cloud 
technologies designed to handle the flow of complex data further characterize the big data revolution.152 
Medical record linkages that capitalize on existing data are increasingly deployed in resource-limited 
settings to strengthen health systems. Data linkages are a versatile and robust tool to efficiently merge 
information across distinct data sources, providing unique insights into clinical and public health 
issues,123-125 but sophisticated technology solutions may not work if they are not tailored to context-
specific challenges of the local environment.  
Implementing data linkage of health records and registries often faces unique challenges in low-and 
middle-income countries. Ubiquitous and consistent forms of identification are a challenge for countries in 
Africa.153 Furthermore, local technology infrastructure and statistical capacity are usually limited,154 and 
systems to collect, disseminate, and use data are typically weak.155 Patient identification numbers, such 
as barcoded IDs on the Malawi health passport, a portable abridged medical record belonging to the 
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patient, may not be consistently noted in local hospital files.  Additional statistical challenges include 
missing data, data accuracy, and absence of gold-standard datasets for validation.  
Therefore, new solutions are needed to maximize implementation of big data approaches in 
resource-limited settings. Case studies with careful assessment of data quality are needed to describe 
solutions to specific analytic and contextual obstacles encountered during data linkage studies in low-and 
middle-income countries.156 In this paper, we present a novel case study from Malawi. In this case study, 
we specifically address the dimension of data veracity as it applies to public health research. The Malawi 
HIV-Cancer Match Study leverages data sources across vertical health programs: a population-based 
cancer registry and clinical systems that support antiretroviral therapy (ART) delivery for HIV. Since HIV 
status is seldom captured by the cancer registry, and cancer outcomes are not typically collected by HIV 
clinics in Malawi, we used a data linkage approach to merge these distinct data sources. The study 
design is innovative in that it employs an approach of probabilistic algorithms for record matching and an 
iterative process of medical chart review. The design is locally tailored to address real-world challenges of 
missing data, outcome misclassification, and case validation. We describe our strategy for assessing 
linkage performance and quality. We share the challenges and lessons learned through this process to 
further the dialogue of field implementation strategies for data linkage in resource-constrained settings.  
 Methods 
Populations  
The Malawi HIV-Cancer Match Study is comprised of two observational cohorts of HIV patients 
receiving ART. In the central region, Lighthouse Trust clinic, located adjacent to at Kamuzu Central 
Hospital, Lilongwe, is the largest public ART provider. Queen Elizabeth Central Hospital is a tertiary 
hospital in Blantyre and the largest referral center in the southern Region. Both HIV clinics use electronic 
medical records to routinely collect demographics, baseline and follow-up clinical data, laboratory tests, 
and ART information.126, 127 Active tracing is used for patient follow-up and ascertainment of vital status. 
Confirmatory HIV diagnosis and WHO clinical staging are provided at time of entry into care.  
The Malawi cancer registry uses active case-finding during cross-sectional surveys of secondary 
(district-level), tertiary (central-level), and major departments of other public and private hospitals. 
Sources of information include outpatient departments, inpatient wards, clinics, laboratory, pharmacy, 
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surgery, and mortuaries.17, 157 Data are coded using the International Classification of Disease for 
Oncology (ICD-O).133 Information on diagnosis and treatment are processed and stored in World Health 
Organization cancer registry software CanReg4.134  
Record linkage study design 
We conducted a data linkage between records from the cancer registry and EMRs from HIV clinics. 
All patients enrolled at Queen Elizabeth Central Hospital from January 1, 2000 – October, 1 2015 were 
eligible regardless of prior cancer diagnosis or length of patient follow-up (N=23,743). Similarly, all 
patients enrolled at Lighthouse Trust from January 1, 2007 – October 1, 2010 were eligible (N=26,977). 
The entire dataset for the cancer registry from 1985-2010 was used for the record linkage (N=62,944).  
Match variables 
A combination of non-unique identifiers (names, birth dates) were used to link the HIV cohorts with 
the cancer registry. In our study, unique identifiers such as a national identification number or cell phone 
numbers were not available, which is a common challenge in many resource limited contexts. Therefore, 
we used a set of demographic variables shared across the data sources to link data files: first name, last 
name, year of birth, sex, and district of residence. Consistent with other African research settings, date of 
birth was estimated for a substantial proportion of records. Therefore, we incorporated a rule allowing for 
a 5-year discrepancy in year of birth between pairs of records.12 
Probabilistic data linkage  
We used probabilistic data linkage to match pairs of records across datasets. We considered two 
main approaches: deterministic and probabilistic methods for linking the datasets together. Deterministic 
linkage groups records using unique or non-unique identifiers, such as names and birth dates, and relies 
on the exact match of one or more identifiers. Probabilistic linkage instead uses the probability of 
matching across a set of variables for a given record pair. 
A match probability and weight is calculated for each potential record pair across each linkage 
variable. The match weight is the likelihood that two records truly match given agreement on a set of 
patient identifiers. A high weight indicates a high degree of similarity between a record pair, and a low 
weight indicates dissimilarity.  Record pairs are then classified by their weights into one of 3 categories 
using a process known as highest-weight classification, resulting in three outcomes: definite match, 
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possible match requiring review, and non-match. Records with the highest weights above a 
predetermined weight threshold are categorized as definite matches, while potential matches require 
review. The weight thresholds used during the classification process are specific both to the data at hand 
and the purpose of the research. Record linkages are typically run iteratively to refine weight thresholds 
(Figure 4-1).136   
Data harmonization and pre-processing   
Data pre-processing is the most labor intensive step of a data linkage. Sophisticated software 
packages and algorithms cannot correct for poor quality baseline data during the linkage. Therefore, the 
success of record linkage is highly dependent on data quality. Pre-processing involves de-duplicating 
records, standardizing formats for variables such as dates, and correcting miscoded or missing data. 
Patient records were consolidated when more than one observation was present per individual.  
Data was pre-processed to harmonize variables across datasets. Greater than 4000 distinct, free-
text patient residences were recoded to the district level in each HIV cohort master file. In the cancer 
registry, hospital facility was used as a proxy for the district of residence when these were missing, except 
if the hospital was one of three major referral centers: Kamuzu Central Hospital, Zomba Central Hospital, 
or Queen Elizabeth Central Hospital. Cancer patients are often diagnosed at the district hospital closest 
to their residence, prior to receiving referral for oncology services in Lilongwe or Blantyre.  
Regular expressions were used for name parsing and removing prefixes, titles, salutations, special 
characters and handling initials. Pre-processing is context and language specific. Beyond issues 
surrounding name changes due to marriage, maiden names, and nicknames, a particular consideration in 
the Malawian context is the variation in the spelling of names. Certain letters are used interchangeably 
such a ‘r’ and ‘l’, ‘y’ and ‘ee’. For example, ‘Graham’ is interchanged with ‘Glaham’, ‘Eviness’ with 
‘Eveness’, ‘Bitya’ with ‘Bitia’, and ‘Jacqueline’ with ‘Jacqureen’.  A consensus on spelling variations and 
nicknames for >8000 Malawian common first and last was established by local data staff for use in 
subsequent steps of review. Also, context specific is the use of salutations that are recorded as part of the 




Highest weight classification of records 
Several iterations of the linkage were run to refine the matching algorithms and weight thresholds 
(Figure 4-2). During the initial iterations, the study team refined match criteria based on a preliminary 
review of randomly sampled record pairs from a range of high to low weights. The sampling was done as 
a qualitative appraisal of the quality of record matches. Descriptive statistics and boxplots were generated 
to visualize the range of weights for each match variable and the overall total weight score for a record 
pair. Linkage rules were then fine-tuned by the study team (MJH, SC, AS) to reflect the importance of 
each variable in predicting a match within our specific database. Linkage algorithms were re-run with the 
new specifications. For example, many people have an estimated birthdate, we reset the criteria for the 
birth year variable to allow a 5-year window for matching and to contribute a lower weight to the total 
weight score.  
The total weight score for each record pair represents the log odds of obtaining a true record pair to 
a true non-record pair given the agreement patterns across the set of 5 match variables. A high weight 
indicates a high degree of similarity between a record pair, and a low weight indicates dissimilarity. 
Negative values represent non-matches. In our study, the total weight scores range from  -28 to 39. The 
study team set the weight thresholds after qualitatively reviewing a random sample of matched record 
pairs for accuracy. Since a priori information of the expected number of cancer matches was unknown, 
we set the weight threshold to maximize sensitivity by including the maximum number of potential 
matches. As in other linkage studies, highest-weight classification (Figure 4-3) was used to classify record 
pairs as definite matches (23≤weight≤39), potential matches (12≤weight<23) or non-matches (-
28≤weight<12), followed by manual adjudication of potential matches. A weight less than 23 in our study 
is the point at which data quality issues or missing data introduce uncertainty, and extra clinical 
information from the HIV medical record or cancer registry is required to make a final determination. In 
primary analysis, definite matches (23≤weights≤39) and the clinically adjudicated matches 
(12≤weights<23) were used for cancer incidence rate calculations. In subsequent sensitivity analyses, we 
calculated rates only using definite matches (23≤weights≤39) to exclude the possibility of false matches; 




Outcome validation  
Since a gold standard dataset was not available for external validation of matches, we conducted a 
two-pass process of clerical and clinical review. Logic rules were constructed to validate highest weight 
definite matches and to further parse potential matches into one of two categories: those requiring further 
clinical review and non-matches. Potential matches were manually inspected to assess whether records 
belonged to the same person. Reviewers (MJH,SC) were blinded to the cancer type during clerical 
review. The study team used a priori criteria consisting of date of birth, when available, date of death, 
date of cancer diagnosis, and hospital location of the cancer diagnosis when residence information was 
missing (Table 4-1). For example, 29% of records in the Lighthouse Trust cohort has missing district of 
residence. Since 15% of people attend clinic solely for an emergency prescription refill, once could not 
assume that those people permanently reside in the metropolitan area of Lilongwe. Therefore, if the 
hospital location of the cancer diagnosis was within proximity of the HIV clinic, we took that as meeting 
the physical presence test of residing in the district. Name variations were reviewed against a directory of 
regionally specific common names and nicknames complied specifically for this purpose by the study 
team.  
Clinical review of potential matches was conducted by three senior Malawian investigators using 
additional oncology treatment data collected by the cancer registry and archival patient records from 
National Oncology Review Board’s External Referral Committee, which documents patients sponsored to 
receive oncology care abroad. Potential matches were reviewed for biological and clinical plausibility 
according to a priori criteria. Reviewers were provided with 1) information pertaining to the cancer 
diagnosis: date of diagnosis, age at diagnosis, cancer type, cancer histology, tumor behavior, basis of 
diagnosis, facility where data was abstracted, treatment, sex; and 2) information pertaining to the ART 
cohort: age at ART enrollment, ART facility, AIDS-defining cancer diagnosis recorded by HIV clinic, if any,  
time between registry cancer diagnosis and start of ART, last date of patient contact, patient outcome as 
of last date of contact. The final match outcome after clinical review were categorized as match, non-






During the final step of linkage post-processing, clinical information from ART clinics was merged in 
the analytical file. All personal identifiers were removed to protect patient confidentiality. An encrypted 
linkage master key containing a matrix of linked IDs and patient names is maintained by the in-country 
analysis team to allow for record linkage updates in the future. 
Statistical analysis 
First, we assessed match performance in each cohort by calculating the match rate, defined as the 
total number of matches divided by the total number of people in each cohort. The quality of the 
probabilistic matching is defined as the proportion of cases that are categorized as high weight “definite 
matches” (weight ≥23) versus low weight “potential matches” (12≤weight <23) requiring further review, 
and the proportion of cases that are discarded due to insufficient information. The study team (MJH,SC) 
used a random sample review of record pairs to set the weight threshold used in highest weight 
classification of “definite” and “potential” matches.  
Second, we examined the impact of missing data on outcome classification during the first step of 
probabilistic matching. To assess the impact of missing data on the highest weight classification of 
records into high weight (weight ≥23) and low weight matches (12≤weight<23), we used Pearson’s chi-
square test of proportions for year of birth (missing versus not missing) and district (missing versus not 
missing).  
Third, we examined the impact of partial agreement of identifiers on outcome classification during the 
first step of probabilistic matching. To evaluate the impact of data quality of the classification of records 
into high weight and low weight matches from the first step of probabilistic matching, we used we used 
Pearson’s chi-square for exact and partial agreement on name and year of birth.  
Fourth, we examined whether individual-level characteristics introduced a systematic bias in the 
linkage of each cohort. We hypothesized that people who were lost to follow-up, transferred out of care, 
or ceased therapy at HIV clinic would be less likely to have a match with the cancer registry.    
Fifth, we qualitatively assessed the specific contextual challenge of how common first names and 
surnames in Malawi reduce the discriminatory power of probabilistic match algorithms. We present the 
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classification of records into definite and potential matches across frequencies of surname in our study 
populations. 
Analyses were conducted in SAS 9.4 (Cary, North Carolina). All significance tests were conducted at 
the α=0.05 level. 
 Results 
Linkage performance  
Probabilistic matching identified a total of 1,269 definite and potential matches across 28,576 new 
ART users across both cohorts (Figure 4-2).  Probabilistic linkage performance varied across cohorts, 
with higher performance yield at QECH compared to LH (QECH: n=731 matches; match rate=6%; LT: 
n=538 matches, match rate=3%). By including the additional steps of clerical and clinical review, 36% to 
75% of potential matches at QECH and LT were discarded due to missing identifiers, inconsistency 
between date of diagnosis and vital status, or insufficient information from the clinical record to make a 
final determination. The post-review match rate remained higher at QECH compared to LT (4% versus 
1%).   
Data completeness and quality 
The level of completeness of identifiers used in the matching algorithms was variable across data 
sources (Table 4-1). First and surname had negligible missing data in both HIV cohorts and in the cancer 
registry. Consistent with other clinical settings in Africa, exact birth date was not routinely recorded in 
health clinics. The majority of records had unknown day and month of birth. Exact month of birth was 
unknown for 27% of records in LT, 40% in QECH, and 85% in the cancer registry. Exact year of birth was 
estimated for 52% of records in LT, and missing for 36% in QECH and 8% in the cancer registry. 
Similarly, district of residence was missing for 9% to 88% of records across data sources. 
Missing data was an important determinant of the large number of potential matches requiring labor 
intensive manual review and adjudication. In Tables 4-2 and 4-3, medium weight matches were 
associated with a greater proportion of missing birth year compared to high weight matches at LT (28% 
versus 2%, p<0.001) and QECH (19% versus 3%, p<0.001). To a lesser extent, medium weight matches 
were associated with a greater proportion of missing district compared to high weight matches at LT (32% 
versus 22%, p=0.05), but not at QECH (56% versus 64%, p=0.06). 
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Imperfect matches on name and birth year also resulted in time and labor intensive manual review 
efforts of medium weight matches. In Tables 4-4 and 4-5, imperfect agreement across all link fields was 
more common for medium weight matches compared to high weight matches for LT (98% versus 61%; 
p<0.001) and QECH (99% versus 89%; p<0.001). Partial agreement across each link field separately, 
except for sex, was consistently more common among low weight matches compared to high weight 
matches.  
Bias analysis 
Vital status and retention in care in clinic were associated with a cancer match outcome at LT Table 
4-6). Among deceased persons the odds of a matched outcome were nearly twice that of people who 
were alive and in care (OR=1.9; 95%CI 1.3, 2.8), after adjusting for age and sex.  A greater odds of a 
match outcome relative to those who remained in care at LT was observed for people who transferred to 
another clinic (OR= 1.5, 95%CI 0.9, 2.2), were lost to follow-up (OR=2.0, 95%CI 1.4, 3.0), or ceased 
antiretroviral therapy (OR=2.6, 95%CI 1.5, 4.3), after adjusting for age and sex.  
People <30 years at the time of enrollment has a reduced odds of matching to the cancer registry 
(OR=0.6, 95%CI 0.4, 0.9) compared to people ages 30-44 years, after adjusting for vital status and sex. 
There was no association between ages older than 45 years (OR=1.0, 95%CI 0.7, 1.5) and female sex 
(OR=1.0, 95%CI 0.8, 1.4) and matching in the cancer registry.  
Onomastics 
Distribution of surnames varied by geographical location of the HIV cohorts in our study. Two 
surnames comprised 7.6% of 9,359 unique names in Lilongwe and 4.1% of 8,517 unique names in 
Blantyre. Because probabilistic weights are a function of 1) the degree of agreement between identifiers 
and 2) the frequency at which identifiers occur in the data, records with common last names tend to 
cluster in the range of medium weight scores (Figure 4-4). At Lighthouse, the low overall match rate was 
in part due to the high proportion of discarded matches (40%) with common surnames occurring at 
frequencies >0.5% (Figure 4-3).  
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 Discussion  
Our case study describes common analytic barriers that may be encountered during complex 
healthcare data linkage studies in LMIC. We evaluated analytic challenges encountered during 
probabilistic linkage of healthcare records from two observational HIV cohorts to a population-based 
cancer registry in Malawi. We used a hybrid approach for the record linkage: probabilistic matching on 
demographic identifiers, followed by labor- and time-intensive manual adjudication of records and clinical 
review. Our hybrid approach was designed to address three main analytic challenges encountered in our 
setting: missing data, reduced resolution of link fields in Malawi, and absence of a gold standard dataset 
for validation of outcomes.   
Data quality and completeness are real-world, practical concerns for the design of linkage studies, 
particularly in resource-limited environments. Missing data and misreporting of patient identifiers 
significantly impacted the overall performance of probabilistic matching in our study. Country-specific 
circumstances such as lack of birth certificates cause substantial missing data on date of birth in clinical 
records in Malawi. In probabilistic matching, the degree of similarity between values of a given variable 
and the weighted contribution of that variable together drive the total weight score for a given record pair. 
159 When either of two values is missing, it is not possible to calculate the similarity distance, and that 
variable contributes nothing to the total weight score. Detailed physical location of patient residence is 
recorded by HIV cohorts for the purpose of active tracing, and is therefore a quasi-unique identifier. 
However, detailed residence information is not available to the cancer registry. The linkage design 
therefore relies on the most common denominator information for patient residence, which is a loss of 
resolution for this highly informative patient identifier. Lastly, time-varying patient demographics such as 
maiden name and residence are generally complex to handle with algorithms alone; manual adjudication 
with extra longitudinal data is usually required. Striving towards consistent and high resolution patient 
identifiers would improve linkage outcomes in the long-term.  
Data errors in match variables may be language and context specific. For example, in Malawi, 
certain letters like ‘r’ and ‘l’ are commonly interchanged in Chichewa, the local Bantu-based language. 
Additional discrepancies may arise from typographical errors occurring during data entry, variations in 
patient demographics, and the use of nicknames. Probabilistic methods are well-suited to handle minor 
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discrepancies such as these136, 143. However, the algorithms also weight the frequency at which identifiers 
occur in the study sample. Common surnames and first names present a major challenge in Malawi 
because they reduce the discriminatory power of linkage on patient name. For example, the two 
surnames “Banda” and “Phiri” account for 7% of names in our study population. Even exact agreement on 
a common name will contribute little to the total summary weight for that record pair. In contrast, rare 
names contribute a high weight towards the overall summary weight of the record pair. Anecdotally, clinic 
staff also reported the use of nicknames and aliases among people enrolling in care due to social stigma 
associated with HIV, creating cultural and disease-specific challenge for our study. This issue may also 
apply to similar efforts focused on stigmatized disease states in low- and middle-income countries.     
A critical step in the linkage process is to assess the performance and quality of linkage, especially 
when the number of expected cases is unknown.160 We evaluated the match rate at each step of the 
linkage process as an indicator of performance. Variations in data quality and completeness of linkage 
fields across study sites likely affected the linkage performance. The greater match rate in Queen 
Elizabeth Central Hospital is likely due to higher completeness of cancer registration activities in that 
region of the country, and richer sources of secondary clinical information with which to triangulate 
matched cases. Insufficient data to make a final decision resulted in a large proportion of cases being 
discarded. The reduced match rate, and large number of “missed links” likely reduced the sensitivity of 
the linkage at Lighthouse, but it was not feasible to directly measure this.  
Taken together, missing data, data errors, legitimate variations in demographic identifiers, and 
country-specific name frequencies jointly lower linkage weights, creating a scenario of uncertainty in the 
‘true’ match status of records. The use of probabilistic algorithms alone in low-and middle-income 
countries may be overly conservative in assigning HIV-cancer matches due to the aforementioned 
underlying analytical challenges in the local healthcare system. A validation step is important to gauge the 
extent of possible measurement error in linkage outcomes, and calibrate analyses accordingly. Since a 
gold standard dataset was not available, our approach therefore used a time and labor intensive review 
process to adjudicate potential matches using additional information abstracted from the medical record. 
In low-and middle-income countries, high quality review may be difficult when secondary information on a 
case is simply not available. Lack of triangulating data to verify links may be a major setback156, and the 
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availability of additional sources of data with which to validate cases should be considered carefully 
during the study planning phase of a healthcare linkage.   
Adding a supplemental review step with external clinical data is a field-tested approach to address 
real-world statistical limitations in a resource-limited setting. When available, biometric-based identifiers 
may also improve the quality of data linkage products. In South Africa, fingerprint scans used as IDs in 
large demographic surveys 161 and in select healthcare centers were used to validate the identify of cases 
in a population-based data linkage.162 Rural Ghana used fingerprint scans as a primary linkage identifier 
between a demographic survey and health centers.163  As fingerprint scans are launched as a primary 
means of national identification in select African countries153, with biometric-based forms of identification 
leapfrogging paper-based methods, it remains to be seen how to best incorporate these new technologies 
into big data approaches in public health. 
 Conclusions  
We demonstrated that a big data approach to public health research is feasible in a low-income 
country. Record linkage is a powerful tool, but presents limitations 160 that warrant transparent discussion 
within the research community. Reporting linkage results and limitations in a transparent manner164 may 
assist with field implementation of similar studies in other countries in Africa. Despite statistical and other 
challenges present in resource-constrained environments, record linkages are an opportunity to invest in 
strengthening health systems. Continued and sustained investments in data quality and completeness 




Panel. Criteria used during clerical review of definite and potential matches. 
Applies to  Logic rules Outcome 
All matches 
(12<weight<40) 
Date of death recorded in ART cohort prior to 




Date of cancer diagnosis prior to date of birth non-match 
All matches 
(12<weight<40) 
Not enough information to assign outcome due 
to missing date of cancer diagnosis  
non-match 
Potential matches 
(12< weight< 23) 
Not enough information to assign outcome due 
to missing year of birth 
non-match 
Potential matches 
(12< weight< 23) 
District of residence is missing, but the location 
of cancer diagnosis is within proximity to the ART 
clinic, therefore the potential match meets the 
“physical presence test” of being present in 






Lilongwe hospitals: ABC Clinic, Kamuzu Central Hospital, Mtengowanthenga, Likuni, Kasungu, City 
Centre Clinic 
Blantyre hospitals: Mwaiwathu Private Hospital, Queen Elizabeth Central Hospital, Mlambe, Chitawira 





Table 4-1. Completeness of identifiers used in probabilistic matching 
  
Lighthouse Trust 
(2007-2010)   
Queen Elizabeth 
Central Hospital 
(2000-2010)   
Malawi Cancer 
Registry      
(1985-2010)  
  N %   N %   N % 







        
Complete surname 26,958 100.0% 23,509 100.0% 62,943 100.0% 











        
Complete First name 26,933 99.9% 23,505 100.0% 62,912 99.9% 










         
Estimated birthdate * 14,106 52.3% n/a n/a 

















Birth Day, estimated 15th 1,364 5.1% 
 
n/a 
   
n/a 
         
District of residence 
        
Blantyre 11 0.0% 749 3.2% 18,478 29.4% 















         
Sex  
        
male  6,626 24.6% 10,278 43.7% 29,630 47.1% 





missing 10,516 39.0%   n/a     2 0.0% 







Table 4-2. Missing characteristics across link fields during each step of the record linkage process, Lighthouse Trust 
  Probabilistic linkage only Probabilistic linkage and review   
  













  N % N % N % p N   N % N % p 
Year of Birth                  
Partial or exact 
agreement 414 77% 98 98% 316 72%   200 99% 93 98% 107 100%   
Missing 124 23% 2 2% 122 28% <0.001 2 1% 2 2% 0 0% 0.13 
                   
District                  
Partial or exact 
agreement 375 70% 78 78% 297 68%   170 84% 75 79% 95 89%   






Table 4-3. Missing characteristics across link fields during each step of the record linkage process, Queen Elizabeth Central Hospital 















  N % N % N % p N % N % N % p 
Year of Birth                 
Partial or exact 
agreement 626 86% 206 97% 420 81%  449 97% 205 97% 244 96%   
Missing 105 14% 6 3% 99 19% <0.001 15 3% 6 3% 9 4% 0.67 
                  
District                 
Partial or exact  
agreement 305 42% 77 36% 228 44%  213 46% 77 36% 136 54%   










Table 4-4. Degree of similarity across link fields during each step of the record linkage process, Lighthouse Trust 
  Probabilistic linkage only Probabilistic linkage and review   
  













  N % N % N % p N % N % N % p 
All identifiers (name, 
year of birth, district, sex)                  
Full agreement 46 9% 39 39% 7 2%   44 22% 39 41% 5 5%   
Partial agreement 492 91% 61 61% 431 98% <0.001 158 78% 56 59% 102 95% <0.001 
                   
Full name and year of 
birth                  
Full agreement 83 20% 55 56% 28 9%   58 29% 51 55% 7 7%   
Partial agreement 331 80% 43 44% 288 91% <0.001 142 71% 42 45% 100 93% <0.001 
                   
Year of Birth                  
Full agreement 198 48% 71 72% 127 40%   102 51% 69 74% 33 31%   
Partial agreement 216 52% 27 28% 189 60% <0.001 98 49% 24 26% 74 69% <0.001 
                   
Full name                  
Full agreement 313 58% 82 82% 231 53%   139 69% 80 84% 59 55%   
Partial agreement 225 42% 18 18% 207 47% <0.001 63 31% 15 16% 48 45% <0.001 
                   
District                  
Full agreement 368 98% 71 91% 297 100%   160 94% 67 89% 93 98%   
Partial agreement 7 2% 7 9% 0 0% <0.001 10 6% 8 11% 2 2% 0.02 
                   
Sex                  
Full agreement 536 100% 100 100% 436 81%   200 99% 95 100% 105 98%   






Table 4-5. Degree of similarity across link fields during each step of the record linkage process, Queen Elizabeth Central Hospital 
  Probabilistic linkage only Probabilistic linkage and review   
  













  N % N % N % p N % N % N % p 
All identifiers (name, 
year of birth, district, sex)                  
Full agreement 31 4% 24 11% 7 1% <0.001 31 7% 24 11% 7 3%   
Partial agreement 700 96% 188 89% 512 99%   433 93% 187 89% 246 97% <0.001 
                   
Full name and year of 
birth                  
Full agreement 124 20% 99 48% 25 6% <0.001 116 26% 98 48% 18 7%   
Partial agreement 502 80% 107 52% 395 94%   333 74% 107 52% 226 93% <0.001 
                   
Year of Birth                  
Full agreement 184 29% 114 55% 70 17%   162 36% 113 55% 49 20%   
Partial agreement 442 71% 92 45% 350 83% <0.001 287 64% 92 45% 195 80% <0.001 
                   
Full name                  
Full agreement 548 75% 190 90% 358 69%   359 77% 189 90% 170 67%   
Partial agreement 183 25% 22 10% 161 31% <0.001 105 23% 22 10% 83 33% <0.001 
                   
District                  
Full agreement 305 100% 77 100% 228 100%   213 100% 77 100% 136 100%   
Partial agreement 0 0% 0 0% 0 0%   0 0% 0 0% 0 0%   
                   
Sex                  
Full agreement 726 99% 212 100% 514 99%   462 100% 211 100% 251 99%   
Disagreement 5 1% 0 0% 5 1% 0.15 2 0% 0 0% 2 1% 0.20 
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Table 4-6. Association of individual-level characteristics among matched and non-matched records, 
Lighthouse Trust 
  
Match  Non-match 
Odds Ratio (95%CI)  N N 
Patient-level follow-up status    
Alive, in care 74 8066 1. 
Lost to follow-up 40 2299 2.0 (1.4, 3.0) 
Stopped therapy 18 783 2.6 (1.5, 4.3) 
Transfer to another clinic 31 2342 1.5 (0.9, 2.2) 
Deceased  39 2224 1.9 (1.3, 2.8) 
missing 0 3   
   
Age group (years) 
   
<30 53 5522 0.6 (0.4, 0.9) 
30-44 117 8009 1. 
45+  32 2187 1.0 (0.7, 1.5)  
   
Sex 
   
Female 91 6622 1. 03 (0.8, 1.4) 












Figure 4-2. Flowchart of cancer registry linkage to HIV patient records (A: Lighthouse Trust; B: Queen 








Figure 4-3. Highest weight classification of linkage outcomes as a function of perfect and partial 






Figure 4-4. Highest weight classification of linkage outcomes as a function of perfect and partial 





CHAPTER 5. HIGH CANCER BURDEN AMONG ANTIRETROVIRAL THERAPY USERS IN MALAWI: 
A RECORD LINKAGE STUDY USING OBSERVATIONAL HIV COHORTS AND CANCER REGISTRY 
DATA 
 Introduction  
Three AIDS-defining malignancies, Kaposi sarcoma (KS), cervical cancer, and non-Hodgkin 
lymphoma (NHL) are among the top 10 cancers in sub-Saharan Africa (SSA), where 70% of global HIV 
burden is concentrated.89,20 Rapid scale-up of ART availability over the past decade89 is likely to affect 
regional cancer burden. In high-income countries, cancer risk among HIV populations is evolving, with 
notable declines in risk of KS, NHL, and some non-AIDS defining cancers (NADC) over the course of 
ART expansion since 1996.165 The burden of certain NADC is now projected to increase and surpass that 
of AIDS-defining cancers (ADC) due to growth and aging of the population living with HIV.166 But 
extrapolations from high-income countries may not apply to SSA, where delays in accessing HIV care are 
substantial, advanced immunosuppression at ART initiation is common167, and prevalence of oncogenic 
viral infections is high.168 Epidemiological evidence is therefore needed to understand current cancer 
trends specifically in SSA.  
In the Malawi HIV-Cancer Match Study, we aim to characterize cancer incidence among ART 
initiators. In Malawi, HIV prevalence is 9% and ART coverage has reached 67%, using a threshold for 
ART eligibility of 500 CD4 cells/µL or WHO clinical stages 3 and 4.14 Our work differs from previous 
studies in the region 12, 116, 117, in that we used two of the largest, actively traced cohorts of ART users in 
the country. We also conducted cross-sectional linkage of cancer outcomes using the population-based 
national cancer registry. Finally, we examined a study period spanning the initiation of national ART 






Study subjects were HIV-infected people receiving ART at Lighthouse Trust (LT) and the Queen 
Elizabeth Central Hospital (QECH) HIV clinics. In the central region, LT in the capital, Lilongwe, is 
Malawi’s largest public ART provider. In the south, the QECH HIV clinic is situated in Blantyre, Malawi’s 
second largest city. LT and QECH use electronic monitoring systems to routinely collect demographic 
information, WHO stage at clinic enrollment, drug regimens, and patient outcomes.126, 127 Active tracing is 
used for patient follow-up and ascertainment of vital status. In Malawi, CD4 count measurement was 
historically restricted to stage 1 and 2 patients who were not clinically eligible for ART (e.g. stages 3 and 
4). For QECH prior to 2011, CD4 counts were not captured in the electronic monitoring system and 
therefore were not available for analysis. Routine HIV RNA monitoring in Malawi did not begin until 2011. 
Therefore, limited CD4 count data and no HIV RNA data were available during the time period of our 
study reflecting practice within the Malawi national HIV program. 
The population-based Malawi Cancer Registry (henceforth, the registry) is a founding member of the 
African Cancer Registry Network and one of only five cancer registries from SSA included in the WHO 
Cancer Incidence on Five Continents monograph.20 Active case-finding is conducted through cross-
sectional surveys of secondary (district-level) and tertiary (central-level) hospitals, and major departments 
of other public and private hospitals. Population-based catchment areas and data collection procedures 
have been described previously.17 During the study period, QECH in Blantyre housed the sole pathology 
laboratory for the entire country; a second laboratory open at Kamuzu Central Hospital, Lilongwe in 
2011.169   Thus, in the 2010 national cancer survey, only 18% of cases were pathologically confirmed, 
with most cancer diagnoses supported by clinical, radiological, and/or laboratory data.17 The registry 
pathology confirmation rate is comparable to that of other population-based cancer registries from 
SSA.170, 171 
Electronic medical record linkage 
In the absence of unique personal identifiers, we used probabilistic algorithms to link electronic 
medical records from ART cohorts with cancer records over periods of geographical overlap between HIV 
clinics and cancer registration. All HIV-infected people initiating ART at QECH from 2000 to 2010 or LT 
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from 2007 to 2010 were eligible based on years of registry coverage in Blantyre and Lilongwe, 
respectively. Electronic medical records (EMR) were matched on first and last name, year of birth, sex, 
and district of residence as these identifiers were shared across datasets. Consistent with other SSA 
settings, date of birth was estimated for a substantial proportion of records. Therefore, only year of birth 
was used as a linkage variable, allowing for 5-year discrepancies between record pairs during 
subsequent iterations of the linkage.12 As in other linkage studies, highest-weight classification was used 
to classify record pairs as matches, potential matches or non-matches, followed by manual adjudication 
of potential matches.12 Potential matches were manually reviewed and validated according to a priori 
criteria.  Potential matches were further validated through clinical review by three senior Malawian 
investigators using additional oncology treatment data collected by the registry and National Oncology 
Review Board, when available. Data preprocessing and probabilistic record linkage were performed in 
KNIME Analytics Platform Version 2.12.1 (Konstanz, Germany)147, an open-platform data miner, utilizing 
the K-Link probabilistic linkage plug-in. Data pre- and post-processing were conducted in Stata 14 (Stata 
Corporation, College Station, Texas). Analyses were conducted in SAS software 9.4 for Windows (Cary, 
NC, USA). The study was approved by the University of North Carolina Institutional Review Board and 
University of Malawi College of Medicine Research Ethics Committee. 
Study design and statistical analysis  
We used an observational multi-cohort design. ART-naïve persons were eligible for analysis if they 
had a first clinic date occurring between January 1, 2000 and August 30, 2010 at QECH and January 1, 
2007 and August 30, 2010 at LT,and were followed for at least 90 days. The event of interest was a first 
primary cancer occurring greater than 90 days after ART start. Cancers were identified either through 
registry linkage or from the cohort EMRs as part of the medical workup for WHO clinical staging and 
patient monitoring. We further classified new cancer as early incident (4 to 24 months after ART start) and 
late incident (>24 months). Person-years (py) at risk for incident cancer was calculated from 90 days after 
ART enrollment to the earliest of cancer diagnosis or censor due to ART cessation, clinic transfer, last 
contact, death, or October 1, 2015 administrative censor. For those lost to follow-up, person-time at risk 
included a 180-day window past the missed appointment date. Cancer diagnoses that were linked 
beyond the last date of contact or 180-day window were excluded from primary analyses (n=36). 
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Subsequent multiple primaries of different anatomical site or histology (n=32) and prevalent malignancies 
defined as a diagnosis prior to enrollment or within 90 days of ART start (n= 3,463) were excluded. 
Cancer data were coded using the International Classification of Disease for Oncology (Table 5-4).133 
Incidence rates (IR) and 95% confidence intervals (CI) were estimated with Poisson regression, 
separately for each cohort, sex, individual cancer sites, early versus late incidence periods, and WHO 
stage at clinic enrollment. We applied direct standardization for age (0-15, 16-25, 25-35, 36-45, 46-55, 
56+ years) and sex (male, female) using population weights from the combined cohorts. For sex-specific 
cancers, we used age-standardization for male and female populations, respectively. We further 
conducted a sensitivity analysis using only cancer matches with the highest linkage weights to estimate a 
conservative lower bound on IR (Table 5-6).  
 Results 
Our study included 28,576 new ART users who initiated care at QECH (n=12,656; Figure 5-2) and 
LT (n=15,920; Figure 5-3). Median age at enrollment was 33 years (Table 5-1). New patients tended to 
initiate ART at an advanced WHO stage (LT stage 3: 41%, stage 4: 14%; QECH stage 3: 50%, stage 4: 
16%). WHO stage distribution differed significantly between clinic sites (p<0·0001), where LT had greater 
proportion of persons with missing WHO stage information (16%) in the EMRs used for our study. 
Overall, 4,346 cancers were identified: 16% were identified through record linkage (LT n=202; QECH 
n=477), 84% through the EMR (LT n=3351; QECH n=528). Pathological confirmation of cancer diagnosis 
was low and varied by clinic site: 3% at LT and 19% at QECH, reflecting diagnostic pathology availability 
in Lilongwe and Blantyre, respectively, during the study period. Prevalence of cancer at time of enrollment 
differed substantially by cohort: 18% of the LT cohort and 5% of QECH presented with malignancies, with 
prevalent cancers being predominantly ADC (98% and 87%, respectively).  
A total of 23,655 cancer-free persons were followed for 100,815 py at risk (LT: n=12,464 individuals; 
n=49,981 py; QECH n=11,191; n=50,834 py; Table 5-1). Most incident cancers occurred within 4 to 24 
months after starting ART (early incident: n=618; late incident n=265). Observed cancer incidence rates 
in our study varied in magnitude across cohorts, and therefore are presented separately rather than as a 
combined point estimate. Overall cancer incidence rate for all sites combined ranged from 488/100 000 
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py (CI: 431, 553) at QECH to 1,257/100,000 py (CI: 1,162, 1,359) at LT (Figure 5-1). Incidence was 
greatest during the early period of 4-24 months following ART initiation).  
AIDS-defining cancers  
KS, cervical cancer and NHL accounted for 98% of new malignancies among patients at LT and 85% 
at QECH (Table 5-4). The majority of KS and cervical cancer cases were diagnosed clinically; 10% and 
27% received a pathological confirmation of diagnosis, respectively. Squamous cell carcinoma was the 
most common type of cervical cancer (42%), followed by non-specified histological types based on 
clinical diagnosis. All NHL cases were pathologically confirmed.  
KS incidence rates ranged from 347 (CI: 288, 402) to 1,204 (CI: 1,111, 1,304) at QECH and LT, 
respectively (Figure 5-1; Table 5-5). KS occurred most frequently in the early incidence period of 4-24 
months after starting ART for both men and women (Table 5-2). Early incident KS ranged from 413 to 
964/100,000 py among men and 267 to 840/100,000 py among women (Table 5-2). Men and women at 
QECH experienced 2 to 9-fold increased incidence of KS at advanced WHO stage relative to early stage 
(Table 5-3); however, this association was not observed among LT patients.  
Cervical cancer was the second most commonly occurring cancer, with an incidence rate ranging 
from 39 (CI: 22, 69) to 108 (CI: 77,153) at LT and QECH (Figure 5-1). No discernable pattern was 
observed in early versus late incidence of cervical cancer (Table 5-2). Women with advanced WHO stage 
had 30-80% lower rates of cervical cancer than women with early stage HIV (Table 5-3).  NHL was 
detected at a low rate in our study (IR: 1.8 to 1.9).  
Non-AIDS-defining cancers 
NADC accounted for 15% of the total cancer burden at QECH and 2% at LT (Table 5-4). At QECH, 
the highest IR were for cancers of the esophagus (13.7), breast (12.9), female reproductive cancers (9.9), 
eye/conjunctiva (8.5), non-melanoma skin (6.3), penis (5.6), colorectum (4.1), unspecified lymphoma 
(3.9), uterus (3.5) and anus (3.0; Figure 5-1; Table 5-5. At LT, the highest IR were for bladder cancer 
(7.9), esophagus (2.2), eye/conjunctiva (1.9), unspecified lymphoma (1.9), larynx (1.9), and lip/oral cavity 
(1.9). 
Pathological confirmation varied across NADC sites: esophagus (19%), cervix (27%), breast (53%), 
anus (75%), lymphomas (100%), oral cavity/pharynx (100%), eye/conjunctiva (100%). Squamous cell 
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carcinoma was the most common type of lip/oral cavity (40%), anus (75%), and eye/conjunctiva (85%) 
malignancy. Squamous cell carcinoma of the esophagus was also predominant (89%). Among breast 
cancers, 71% were infiltrating ductal carcinoma. Infection-associated cancers linked to H. pylori 
(stomach), hepatitis B and C virus (liver), schistosomiasis (bladder), and Epstein-Barr virus (Hodgkin 
lymphoma subtypes) were rarely detected in our study (Figure 5-1). 
 Discussion  
Our goal in the Malawi HIV-Cancer Match Study was to characterize the burden and spectrum of 
cancer among ART users in Malawi, where HIV prevalence is 9% and one in twenty Malawian adults is 
now on ART.14 In our study of nearly 29,000 ART users, the overall cancer burden was high and 
predominantly driven by ADC, even during the era of improving access to ART.  KS was the most 
common cancer, and ADC were a common reason for presenting to care: 4% to 17% of patients 
presented to care with prevalent malignancies. The incidence of new KS was most pronounced during the 
first two years of ART, but remained high over long-term follow-up. Our KS incidence estimates in Malawi 
are among the highest for ART users in SSA, with other reported rates including 77 per 100,000 py in 
Zimbabwe, 169 in Zambia172, 270 in Kenya, 340 in Uganda173, and 432 in South Africa.116 High incidence 
of KS at LT in 2007-2010 and QECH in 2000-2010 are similar in magnitude to ART users with CD4 count 
<50 (IR: 1,523 per 100,000py) and CD4 count 51-100 (IR: 716) in East African ART populations.173 High 
KS burden in Malawi is likely attributable to the 35% to 88% prevalence of the causative virus human 
herpesvirus-8 (HHV-8) in Southern Africa174, and typically advanced HIV stage with late presentation to 
care among ART initiators. This is especially true during the relatively early period of ART scale-up 
analyzed, which began in Malawi in 2004. KS burden may therefore still decline as the national ART 
program matures with earlier and more widespread application of ART. 
Reflecting late presentation to care, advanced WHO stage was associated with increased KS 
incidence, although this association was not observed as strongly across both cohorts perhaps owing to 
differences in competing risk of death and prevalence of persons who already had KS at ART initiation. At 
QECH, advanced HIV stage was associated with a 2- to 10-fold increase in KS incidence. Cervical cancer 
was the second commonest cancer, and more advanced WHO stage was not associated with increased 
incidence of cervical cancer in our study. These findings might suggest KS burden will be more 
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immediately impacted by earlier ART application in SSA than cervical cancer, as also suggested by early 
epidemiological  data from Uganda and Botswana showing modest incidence declines for KS but not 
cervical cancer.11, 13 
We also observed a range of NADC even among Malawians with relatively advanced HIV prior to 
ART initiation. While NADC incidence rates were low overall, our findings highlight the heterogeneous 
cancer burden among Malawian ART initiators beyond KS and cervical cancer, as also suggested by 
other regional studies.11, 13, 175 The highest incidence rates observed were for breast, esophageal, other 
female reproductive, eye/conjunctiva, and bladder cancers. Of these, only other female reproductive 
cancers and bladder cancer have confirmed etiologic associations with infectious pathogens (human 
papilloma virus and schistosomiasis, respectively), but associations with HIV in SSA are uncertain. For 
esophageal cancer, there is no known infectious etiology176, although a Zambia case-control study 
suggested possible association with HIV177. For breast cancer, large studies from high-income countries 
have repeatedly shown reduced risk among HIV-infected persons.165 However, SSA studies from 
Botswana and South Africa have reported HIV prevalence among breast cancer patients that is 
substantially higher than the general population. 25,32 Our work and that of others thus highlight the need 
for larger and more definitive epidemiological  studies to define relationships between HIV and cancer 
which may be unique to SSA, to inform comprehensive, holistic cancer screening and prevention 
programs in regional ART clinics.  
Differences in screening, diagnostic confirmation and referral patterns likely contributed to 
geographical variation in observable KS and cervical cancer incidence in our cohorts, and overall 
completeness of cancer ascertainment by the registry. This observation is similar to the overall context of 
cancer ascertainment in SSA, for which regional limitations have been extensively described.178 The 
lower than expected incidence of lymphomas and NADC in our study is likely due to underdiagnosis. 
During the study period, a single pathology center in Blantyre provided services to the entire country, and 
only approximately one-fifth of all cancer cases in the registry were thus pathologically confirmed. 
Lymphomas may be particularly susceptible to misdiagnosis, and studies from Uganda and Malawi have 
shown that lymphomas are commonly clinically misdiagnosed as tuberculosis.179,180 Our study may also 
be subject to underreporting of cancer incidence during late patient follow-up. The last registry survey 
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occurred in 2010; therefore, diagnoses occurring during follow-up beyond 2010 are not captured by the 
registry. Furthermore, study cohorts are young, and longer follow-up and additional linkages may be 
needed to monitor these populations as they age into a demographic group where NADC are most 
common. In Malawi, a demographic shift among people living with HIV is underway, where patients older 
than 50 years represent a growing proportion of ART users.167 
The Malawi HIV-Cancer Match Study used probabilistic record linkage algorithms to ascertain cancer 
outcomes at centers of excellence for HIV care. This is one of the largest epidemiological studies of its 
kind in SSA to provide a comprehensive overview of the cancer burden among persons receiving ART. 
We used information on active patient follow-up to construct a retrospective cohort of approximately 
29,000 new ART initiators.  Given typically low-quality data sources for robust epidemiological studies in 
SSA, innovative approaches are needed to overcome cancer surveillance obstacles. Our study leveraged 
probabilistic methods and extensive clinical review to link data from Malawi’s national cancer registry with 
existing electronic medical systems supporting ART delivery within large HIV clinics. This strategy is 
highly efficient for Malawi in terms of time and cost and imposed little additional burden on the health care 
system. We performed validation of cancer outcomes through extensive clerical and clinical review of 
matched cases. Our results on the occurrence of a broad spectrum of malignancies are an important 
baseline against which to monitor potential future shifts in evolving cancer burden among persons living 
with HIV. 
Our study has downstream implications for strengthening health systems in Malawi, and improving 
data quality and completeness is a long-term priority. Our study used high quality data from HIV clinics 
participating in the International epidemiologic Databases to Evaluate AIDS (IeDEA) consortium. 
However, a substantial proportion of KS, cervical cancer and lymphoma may not be systematically 
recorded in electronic monitoring outside of HIV centers of excellence. Querying new data sources and 
validation studies using other clinics for HIV, palliative care, and women’s health may improve cancer 
surveillance among HIV-infected populations in SSA. Together, these lessons underscore the importance 
of interdisciplinary collaboration181  between HIV and cancer systems to build efficient and complete 
public health data resources in low-income settings.  
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In conclusion, we provide the first comprehensive baseline description of cancer burden against 
which to monitor cancer control efforts for HIV-infected populations in Malawi.  Our findings demonstrate 
an ongoing high burden of KS and cervical cancer in a young, urban patient population, and the 
importance of integrated screening and management of KS and cervical cancer in ART programs. 
Validation of our findings through companion studies in other parts of SSA is needed, as well as longer-
term studies to monitor potential shifts in cancer distribution with ART scale-up. Continued investment in 




Table 5-1. Characteristics of naïve ART initiators enrolled at Lighthouse Trust HIV Clinic (2007-2010) and 
Queen Elizabeth Hospital HIV clinic (2000-2010). 
  LT (2007-2010) QECH (2000-2010) 
 Total cohort 
Person-years at 
risk  Total cohort 
  
Person-years at risk  
 N % N % N % N % 
Total  15920  49980  12656  50833  
 
Sex         
Male 6713 42% 19557 39.1% 5529 43.7% 20590 40.5% 
Female 9207 58% 30422 60.9% 7127 56.3% 30243 59.5% 
 
Age category 
(years)         
<16  706 5% 2181 5% 1730 14% 6182 12% 
16-25 1641 11% 4881 10% 1203 910% 4048 8% 
26-35 6273 41% 19980 42% 4628 37% 18641 37% 
36-45 4527 30% 14421 30% 3283 26% 14217 28% 
46-55 1624 11% 5012 10% 1321 10% 5799 11% 
56+ 595 4% 1652 3% 491 ‘% 1944 4% 





(IQR) 33.3 (27.9, 39.8)   33.5 (16.7, 40.9)   
 
WHO stage           
1 or 2 4852 31% 17693 35% 4181 33% 18792 37% 
3 6499 41% 19362 39% 6261 50% 26122 51% 
4 2207 14% 4855 10% 2010 16% 5476 11% 
Not applicable/ 
unknown 
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Table 5-2. Cancer incidence rates by timing of diagnosis after ART initiation 
  Men  Women 
 LH QECH LH QECH 
 IR (95% CI) IR (95% CI) IR (95% CI) IR (95% CI) 
All sites, total  1255.0 (1107.7, 1421.8) 585.0 (489.3, 699.3) 1257.3 (1137.3, 1390.1) 423.0 (355.7, 503.1) 
   Early incidence  964.6 (836.6, 1112.1) 413.3 (334.2, 511.1) 840.2 (743.1, 949.9) 267.4 (215.0, 332.5) 
   Late incidence  290.4 (224.0, 376.4) 171.7 (123.5, 238.7) 417.2 (350.5, 496.6) 155.7 (117.0, 207.2) 
 
Kaposi sarcoma          
   Early incidence  926.1 (800.8, 1070.9) 388.5 (312.0, 483.7) 797.8 (703.3, 904.9) 184.7 (142.0, 240.3) 
   Late incidence  280.7 (215.6, 365.4) 140.5 (97.6, 202.3) 404.7 (339.0, 483.0) 44.3 (25.9, 75.8) 
 
Cervical cancer         
   Early incidence  -  -  30.1 (15.7, 57.9) 43.1 (25.0, 74.3) 
   Late incidence  -   -   9.8 (3.1, 30.8) 66.2 (42.7, 102.8) 
Early incidence: 4 - 24 months after beginning ART; late incidence: >24 months after beginning ART 
IR: incidence rates per 100,000 person-years on ART, direct standardized for sex-age categories using combined cohorts as standard population 
95% CI : 95% Confidence Interval 







Table 5-3. Cancer incidence rates and incidence ratios by WHO clinical stage 
  Men   Women   
 LH   QECH   LH   QECH   
Kaposi sarcoma IR (95% CI) 
IRR 
  IR (95% CI) IRR IR (95% CI) IRR IR (95% CI) IRR 
   stage 1 or 2 393.4 (315.3, 490.9) 1. 43.7 (22.6, 84.6) 1. 299.5 (243.8, 367.8) 1. 40.4 (23.1, 70.8) 1. 
   stage 3 236.2 (177.5, 314.3) 0.6 86.1 (53.8, 137.8) 2.0 138.9 (102.5, 188.1) 0.5 38.6 (21.8, 68.1) 1.0 
   stage 4 568.5 (472.9, 683.4) 1.4 399.8 (321.4, 497.4) 9.2 25.4 (12.5, 51.7) 0.1 149.0 (111.2, 240.3) 3.7 
 
Cervical cancer             
   stage 1 or 2 - -  - -  19.0 (8.4, 43.0) 1. 44.3 (25.9, 75.7) 1. 
   stage 3 - -  - -  13.1 (4.9, 35.0) 0.7 57.3 (35.8, 91.8) 1.3 
   stage 4 - -    - -   - - - 7.1 (1.9, 27.1) 0.2 
IR: incidence rates per 100,000 person-years on ART, direct standardized for sex-age categories using combined cohorts as standard population 
95% CI : 95% Confidence Interval 
IRR: Incidence Rate Ratio 




E. Supplementary materials 
Figure 5-2. Flowchart of cancer registry linkage to Queen Elizabeth Central Hospital 
 




Highest weight classification and validation 
The analytic team set the final weight thresholds using iterative review of a random sample of record 
pairs and manually reviewed potential matches while blinded to the cancer site. Highest weight 
classification was used to group record pairs into “definite matches” (weight ≥23) and “potential matches” 
requiring further review (weights 12 to 23), and “definite non-matches” (weights <12). In a first round of 
clerical review, date of HIV clinic enrollment, date of cancer diagnosis, date of death, location of cancer 
diagnosis, and a Malawi-specific names thesaurus were used to adjudicate potential matches. Potential 
matches with missing birth year were excluded due to insufficient information.  A second round of clinical 
review was conducted by three senior Malawian clinicians using additional oncology treatment data 
collected by the cancer registry and National Oncology Review Board. Potential matches were reviewed 
for biologic and clinical plausibility using additional information 1) pertaining to the cancer diagnosis: date 
of diagnosis, age, cancer type, cancer histology, tumor behavior, basis of diagnosis, hospital facility, 
treatment, sex; and 2) information pertaining to the HIV cohort: age at start of ART, AIDS-defining cancer 
diagnosis recorded by the facility, if any, time between MCR cancer diagnosis and ART start, last date of 
patient contact and outcome. The final match outcome after clinical review were categorized as match, 








Table 5-4. Frequency of observed cancers by HIV clinical cohort 
      LT   
Primary site ICD-O site ICD-O morphology  
Incident Prevalent Total 
N % N % N % 
Kaposi 




8000, 8010, 8070, 8071, 
8140, 8384 14 (2.2%) 115 (4.0%) 129 (3.7%) 
Non-
Hodgkin 
lymphoma - 9591 1 (0.2%) 0 (0.0%) 1 (0.0%) 
         
Anus 
C21.0-
C21.8 8070, 8140 0 (0.0%) 2 (0.1%) 2 (0.1%) 
Bladder 
C67.0-
C67.9 8070 4 (0.6%) 0 (0.0%) 4 (0.1%) 
Bone 
C40.0-
C40.9 8810, 9731 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Breast 
C50.0-
C50.9 8010, 8140, 8500 0 (0.0%) 4 (0.1%) 4 (0.1%) 
Colorectum 
C18.2-




C69.9 8010, 8070, 9510 1 (0.2%) 3 (0.1%) 4 (0.1%) 
Ear C30.1 8001 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Esophagus 
C15.0-
C15.0 8000, 8010, 8070 1 (0.2%) 6 (0.2%) 7 (0.2%) 
Kidney 64.9 8321, 8960 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Larynx 
C32.0-





8010, 8070, 8071, 8200, 
8941 0 (0.0%) 3 (0.1%) 3 (0.1%) 
Liver 
C22.0-
C22.1 8170 0 (0.0%) 1 (0.0%) 1 (0.0%) 
Lymphoma         
Burkitt 
lymphoma - 9687 0 (0.0%) 1 (0.0%) 1 (0.0%) 
Hodgkin 
lymphoma - 9650 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Lymphoma, 
other 
specified - 9714, 9727 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Lymphoma, 
unspecified - 9590 1 (0.2%) 2 (0.1%) 3 (0.1%) 









C52.9 8010, 8070 3 (0.5%) 1 (0.0%) 4 (0.1%) 
Uterus 
C54.0-
C54.9  0 (0.0%) 2 (0.1%) 2 (0.1%) 
Pancreas 
C25.0-
C25.0 8140 0 (0.0%) 0 (0.0%) 0 (0.0%) 
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      LT   
Primary site ICD-O site ICD-O morphology  
Incident Prevalent Total 
N % N % N % 
Penis 
C60.0-
C60.9 8070 0 (0.0%) 0 (0.0%) 0 (0.0%) 








9590 0 (0.0%) 5 (0.2%) 5 (0.1%) 
Soft tissue 
C49.0-
C49.9 8002, 8901 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Stomach 
C16.0-
C16.9 8240 0 (0.0%) 1 (0.0%) 1 (0.0%) 
Thyroid C73.9 8331 0 (0.0%) 1 (0.0%) 1 (0.0%) 
Unknown 
primary site C80.9 8000, 8070 1 (0.2%) 0 (0.0%) 1 (0.0%) 
Total     
64
1   
285




      QECH 
Primary site ICD-O site ICD-O morphology  
Incident             Prevalent    Total 
N % N % N % 
Kaposi 
sarcoma - 9140 172 (71.1%) 493 (81.5%) 665 (78.5%) 
Cervix uteri C53.0-C53.9 
8000, 8010, 8070, 
8071, 8140, 8384 32 (13.2%) 32 (5.3%) 64 (7.6%) 
Non-Hodgkin 
lymphoma - 9591 1 (0.4%) 8 (1.3%) 9 (1.1%) 
         
Anus C21.0-C21.8 8070, 8140 2 (0.8%) 0 (0.0%) 2 (0.2%) 
Bladder C67.0-C67.9 8070 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Bone C40.0-C40.9 8810, 9731 1 (0.4%) 1 (0.2%) 2 (0.2%) 
Breast C50.0-C50.9 8010, 8140, 8500 4 (1.7%) 9 (1.5%) 13 (1.5%) 
Colorectum C18.2-C20.9 8140 2 (0.8%) 1 (0.2%) 3 (0.4%) 
Conjunctiva, 
Retina, Eye C69.0-C69.9 8010, 8070, 9510 4 (1.7%) 18 (3.0%) 22 (2.6%) 
Ear C30.1 8001 1 (0.4%) 0 (0.0%) 1 (0.1%) 
Esophagus C15.0-C15.0 8000, 8010, 8070 7 (2.9%) 4 (0.7%) 11 (1.3%) 
Kidney 64.9 8321, 8960 0 (0.0%) 3 (0.5%) 3 (0.4%) 
Larynx C32.0-C32.9 8070 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Lip, Oral 
Cavity C00.0-C10.1 
8010, 8070, 8071, 
8200, 8941 0 (0.0%) 2 (0.3%) 2 (0.2%) 
Liver C22.0-C22.1 8170 0 (0.0%) 2 (0.3%) 2 (0.2%) 
Lymphoma         
Burkitt 
lymphoma - 9687 2 (0.8%) 0 (0.0%) 2 (0.2%) 
Hodgkin 
lymphoma - 9650 1 (0.4%) 3 (0.5%) 4 (0.5%) 
Lymphoma, 
other 
specified - 9714, 9727 0 (0.0%) 2 (0.3%) 2 (0.2%) 
Lymphoma, 
unspecified - 9590 2 (0.8%) 8 (1.3%) 10 (1.2%) 
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      QECH 
Primary site ICD-O site ICD-O morphology  
Incident             Prevalent    Total 
N % N % N % 






C51.0-C52.9 8010, 8070 3 (1.2%) 1 (0.2%) 4 (0.5%) 
Uterus C54.0-C54.9  1 (0.4%) 1 (0.2%) 2 (0.2%) 
Pancreas C25.0-C25.0 8140 1 (0.4%) 0 (0.0%) 1 (0.1%) 
Penis C60.0-C60.9 8070 1 (0.4%) 1 (0.2%) 2 (0.2%) 







9590 3 (1.2%) 4 (0.7%) 7 (0.8%) 
Soft tissue C49.0-C49.9 8002, 8901 1 (0.4%) 1 (0.2%) 2 (0.2%) 
Stomach C16.0-C16.9 8240 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Thyroid C73.9 8331 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Unknown 
primary site C80.9 8000, 8070 0 (0.0%) 3 (0.5%) 3 (0.4%) 






Table 5-5. Cancer incidence rates by HIV clinical cohort 
  LH (2007-2010) QECH (2000-2010) 
  IR (95% CI) Rank IR (95% CI) Rank 
All sites  1257.1 (1162.5, 1359.4)  488.3 (431.2, 553.0)  
Kaposi Sarcoma  1204.2 (1111.7, 1304.3) 1 347.5 (299.8, 402.7) 1 
Cervix  39.3 (22.3, 69.4) 2 108.8 (77.3, 153.1) 2 
Non-Hodgkin lymphoma  1.8 (0.2, 14.2) 9 1.9 (0.3, 14.0) 20 
Anus  -   3.9 (1.0, 15.7) 11 
Bladder  8.0 (3.0, 21.3) 3 -   
Bone -   2.2  15 
Breast -   12.9 (4.8, 34.9) 4 
Colorectum -   4.1 (1.1, 15.9) 9 
Conjunctiva, Retina, Eye 2.0 (0.3, 14.2) 5 8.4 (3.3, 21.7) 6 
Ear -   2.0 (0.3, 14.0) 16 
Esophagus 2.2 (0.3, 14.3) 4 13.7 (6.5, 28.7) 3 
Kidney -   -   
Larynx 2.0 (0.3, 14.2) 5 -   
Lip, Oral Cavity -   -   
Liver -   -   
Lymphoma       
Burkitt lymphoma -   2.5 (0.4, 14.2) 14 
Hodgkin lymphoma -   2.0 (0.3, 14.0) 16 
Lymphoma, other specified -   -   
Lymphoma, not otherwise  
specified 2.0 (0.3, 14.2) 5 4.0 (1.0, 15.8) 10 
Ovary  -   3.2 (0.4, 23.5) 13 
Other female reproductive,   
Vulva, Vagina  -   10.0 (3.2, 30.9) 5 
Uterus  -   3.6 (0.5, 23.6) 12 
Pancreas -   2.0 (0.3, 14.0) 16 
Penis  -   5.1 (0.7, 34.5) 8 
Prostate  -   -   
Skin malignancies, non-  
melanoma -   6.3 (2.1, 18.9) 7 
Soft tissue -   2.0 (0.3, 14.0) 16 
Stomach -   -   
Thyroid -   -   
Unknown primary site 2.0 (0.3, 14.2) 5 -     
IR: Incidence rates per 100,000 person-years on ART, direct standardized for sex-age categories using combined 
cohorts as standard population; 95% CI : 95% Confidence Interval 




Sensitivity analysis  
We estimated a conservative lower bound of cancer incidence rates using only “definite matches” 
identified through highest weight classification or the HIV clinic electronic medical record (LT n=3420; 
QECH n= 657). 
 
Table 5-6. Sensitivity analysis: site-specific cancer incidence rates, by HIV clinical cohort 
  LH (2007-2010) QECH (2000-2010)     
  IR (95% CI) Rank IR (95% CI) Rank 
    
All sites  1224.5 (1131.2, 1325.5)  359.9 (311.4, 416.0)  
    
Kaposi Sarcoma  1194.9 (1102.8, 1294.7) 1 295.5 (251.8, 346.7) 1     
Cervix  20.0 (9.0, 44.3) 2 45.9 (27.1, 77.7) 2     
Non-Hodgkin lymphoma  1.8 (0.2, 14.2) 6 - -  
    
Anus  -   3.9 (1.0, 15.7) 7 
    
Bladder  4.0 (1.0, 16.0) 3 -   
    
Bone -   - -  
    
Breast -   9.9 (3.2, 30.7) 3 
    
Colorectum -   2.2 (0.3, 14.0)  
    
Conjunctiva, Retina, Eye 2.0 (0.3, 14.2) 5 4.3 (1.2, 16.2) 6     
Ear -   -   
    
Esophagus 2.2 (0.3, 14.3) 4 5.7 (1.8, 18.0) 5     
Kidney -   -   
    
Larynx -   -   
    
Lip, Oral Cavity -   -   
    
Liver -   -   
    
Lymphoma       
    
Burkitt lymphoma -   -   
    
Hodgkin lymphoma -   2.0 (0.3, 14.0) 10 
    
Lymphoma, other  
specified -   -   
    
Lymphoma, not otherwise  
specified -   2.0 (0.3, 14.0) 10 
    
Ovary  -   -   
    
Other female reproductive,  
Vulva, Vagina  -   7.1 (1.9, 27.1) 4 
    
Uterus  -   3.6 (0.5, 23.6) 8 
    
Pancreas -   2.0 (0.3, 14.0) 10 
    
Penis  -   -   
    
Prostate  -   -   
    
Skin malignancies, non- 
melanoma -   2.2 (0.3, 14.0) 9 
    
Soft tissue -   -   
    
Stomach -   -   
    
Thyroid -   -   
    
Unknown primary site -     -         
IR: Incidence rates per 100,000 person-years on ART, direct standardized for sex-age categories using 
combined cohorts as standard population; 95% CI : 95% Confidence Interval 




CHAPTER 6. CONCLUSIONS  
A. Summary of findings 
We conducted one of the largest epidemiological studies of its kind in SSA to provide a 
comprehensive overview of the spectrum of cancers among people receiving ART. Our multicohort study 
is comprised of nearly 29,000 actively traced patients receiving ART and is a unique resource for SSA, 
where high-quality cancer registries cover only 1% of the population with HIV status rarely captured. To 
overcome local constraints in healthcare infrastructure, we applied innovative and efficient data solutions 
to link cases from the Malawi Cancer Registry with centers of excellence for HIV care in Malawi. Our 
statistical design meant to address the primary analytic challenges encountered in our setting: missing 
data, uncertain linkage because of loss of resolution for patient identifiers in Malawi and other factors, and 
absence of a gold standard dataset for validation of outcomes. Such issues related to data quality and 
completeness are practical concerns for the design of linkage studies, particularly in resource-limited 
environments. Missing data and misreporting of patient identifiers likely resulted in a high number of 
records that failed to link, and perhaps to a lesser degree, false positive links. Consequently, missing data 
on potential matches may have diminished sensitivity of the linkage algorithms, although quantifying the 
impact of missing data on sensitivity and specificity was not feasible due to lack of a gold-standard 
dataset with which to cross-validate our results. We therefore employed an additional review step using 
supplemental information from the medical record as a field-tested approach to address linkage 
measurement error in a rigorous way when sufficient secondary clinical information was available. Our 
study is a proof of concept of a linkage study design tailored to observational, routinely collected data in 
SSA.   
We identified 883 incident malignancies among 23,655 persons who were cancer-free at time of 
enrollment and followed for 100,815 person-years. KS and cervical cancer were the most common 
cancers in this young population of ART users who tend to present to care with severe 
immunosuppression. Rates of KS are among the highest reported to date in the region and are of similar 
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magnitude to what is observed among profoundly immunocompromised people in East Africa. Regarding 
the timing of disease, most incident KS occurred within the first two years of starting ART, and elevated 
incidence rates persisted over the course of patient follow-up in spite of therapy. Men and women 
presenting with advanced stage HIV at the start of ART experienced elevated incidence of KS relative to 
those with early stage of disease. However, more advanced WHO clinical stage was not associated with 
increased incidence of cervical cancer in our study. Our findings suggest that the burden of KS burden 
may be more immediately impacted by earlier ART application in Malawi than cervical cancer, which is 
consistent with data from Uganda and Botswana showing modest incidence declines for KS but not 
cervical cancer.11, 13 Our results not withstanding, earlier application of ART, and therefore the timing of 
earlier immune reconstitution relative to HPV infections and cervical lesions, is critical to control the 
progression of neoplastic cervical lesions to invasive cancer. 182 
AIDS-associated non-Hodgkin lymphomas and a heterogeneous spectrum of NADC were also 
observed, but at low incidence rates. The overall young age distribution of the study population and 
underdiagnosis resulting from limited cancer diagnostic capacity in Malawi are likely factors that lead to 
low rates of NADC and lymphomas observed in our study. 
 Public health implications 
Recent attention has focused on evolving cancer risk in aging HIV populations in the United 
States.165 An emerging public health question is whether these cancer trends will be replicated in SSA 
now that access to ART has become more widespread, and demographic shifts among African ART 
populations are underway. Epidemiologic studies addressing this question have been few within the 
region, and historically, have been hampered by a paucity of data. Public health data linkages are a cost-
efficient strategy for bridging the knowledge gaps between clinical and population sciences and infectious 
disease and noncommunicable disease research silos in SSA. 
Our study shows that cancer burden among Malawian ART users does not yet mirror high-income 
countries. Malawi bears a high burden of AIDS-defining malignancies among young patient populations of 
ART users. It is worth emphasizing that Malawi’s HIV treatment program is still maturing relative to that of 
high income countries, where HAART became widely implemented into clinical practice in 1996. In 
contrast, Malawi’s national ART program began nearly a decade later in 2004, with ART coverage 
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reaching half of all eligible patients by 2011. In our study, median age at the start of therapy was 33 years 
and mean time on ART was 4.5 years, which together may not be a sufficient window of time to observe 
reductions in KS incidence and the development of NADC in our cohorts. Our results reflect clinical 
practice through 2010, when ART was reserved for those with severe immunosuppression. Therapy 
guidelines have since been revised to include patients with higher CD4 counts.  
 Our work has implications for monitoring the impact of earlier application of ART on KS incidence in 
Malawi, where expanded eligibility criteria among adults now include WHO stage 1 or 2 and CD4 counts 
≤500 cells/mm3 , WHO stage 3 or 4 regardless of CD4 count, and universal ART for HIV-infected 
pregnant and breastfeeding women (Option B+).16 ART plays a vital role in the treatment and primary 
prevention of AIDS-related KS, and improves survival among KS patients.183 Early application of ART has 
been shown to dramatically reduce KS incidence at population level in ecologic studies11 and at the 
individual level in IeDEA and other prospective cohorts in Africa172, 173, 184, but additional studies are 
needed to confirm and validate the impact in other SSA populations. East African ART users in Uganda 
and Kenya experienced 80% and 50% reductions in KS incidence rates compared to HIV-infected ART-
naïve persons, though absolute rates of KS remained very high at CD4 counts <350 cells/mm3 even 
among ART users, and significantly elevated relative to ART users in high-income settings.173  
Our work also has implications for monitoring the impact of cervical cancer screening and 
management programs among ART users in Malawi. Effective screening and early treatment of 
precancerous cervical lesions are critical to reduce the burden of cervical cancer. In low- and middle-
income countries, WHO recommends a “screen and treat” approach of visual inspection with acetic acid 
(VIA) and crytotherapy or LEEP for premalignant lesions during a single-day visit, and screening for all 
women and girls with HIV upon a positive HIV result.185 Malawi’s cervical cancer screening program 
began in the 1980s, and since 2004, Malawi’s Ministry of Health introduced a program to scale-up VIA 
and cryotherapy treatment of precancerous lesions to all 29 district hospitals and 3 central hospitals.186 
The program targets women ages 30-49 and those receiving ART, with recommended screening once 
every five years for HIV-uninfected women and once every two to three years for HIV-infected women. 
There are now more than 100 facilities currently delivering VIA, 32 offering cryotherapy, and 3 offering 
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LEEP in Malawi.187, 188 However, uptake of services remains low with approximately one in four eligible 
women accessing screening.189  
Recently, some have called for a standalone policy for cervical cancer prevention and treatment in 
Malawi. 189,190, 191 Many policy and health systems challenges persist.192 Current policy does not 
specifically address poor screening uptake among vulnerable populations such as women living with HIV 
nor screening of women younger than 30 who live with HIV. Another major concern is failure to treat a 
large proportion of VIA-positive women with cryotherapy/LEEP. 2,189 Lastly, there is no quality assurance 
or mandate currently to monitor the effectiveness of the screening program.193 
Further strengthening and integrating cervical cancer screening into HIV ART programs is a critical 
direction for cancer control and prevention in the era of ART.194 Women on ART are under regular clinical 
observation and therefore ART facilities may help address the challenge of high lost-to-follow rates of 
people who do not return for a one year follow-up visit after cryotherapy.189 Operationalizing further data 
linkages is also an opportunity to monitor and evaluate the effectiveness of screening and continued ART 
scale-up on invasive cervical cancer incidence in Malawi.  Updating the design of the cancer registry to 
include VIA data from sentinel HIV clinics would contribute towards the goal of more complete cancer 
surveillance and evidence-based evaluation of screening programs for women living with HIV in Malawi.  
 Strengths 
Our study has several design strengths which improve upon the limitations of previous work 
describing HIV-associated cancer trends in SSA. Linkage of existing data from EMRs is efficient in terms 
of time and cost, and imposes no additional burden on routine delivery of care by local clinicians. We 
used data from the Malawi cancer registry, which is one of only four population-based cancer registries in 
SSA that contributes to global estimates of disease in IARC’s Cancer In V Continents.20   
Our longitudinal cohort design uses a well-enumerated denominator of HIV patients. The selected 
ART cohorts are participating members in the IeDEA worldwide consortium. Since the registry does not 
routinely collect HIV status, we linked patient-level data from the largest tertiary ART clinics within Malawi 
to the cancer registry. This new dataset incorporates HIV clinical assessments, drug regimens, active 
follow-up, and patient vital status. The study’s large sample size was advantageous for exploring the 
distribution of site-specific non-AIDS defining cancers. Similarly, active patient follow-up in the cohorts 
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provided a unique opportunity to study the timing of cancer outcomes in a population of ART users in 
SSA.  
 Our study has several analytic strengths that contribute new insights into the implementation of 
healthcare record linkages for resource-limited settings. Our approach to handling record linkage 
measurement error is transparent, and tailored to directly address data concerns and ethnographic 
considerations specific to the SSA research setting, and may serve as a practical guide to other groups 
seeking to implement and scale healthcare linkages in low- and middle-income countries.   
 Limitations 
Our study does not have a gold-standard dataset against which to validate the record linkage 
performance. The majority of cancer diagnoses recorded in the cancer registry and in the ART cohorts do 
not overlap due to local patterns of care in Malawi. Therefore, the construction of an ad hoc validation 
dataset was not possible.  
 Possible cancer underascertainment at both ends of the study period is a limitation to our 
estimations of cancer prevalence and incidence rates. The 2000-2003 period may underestimate the true 
burden of prevalent NADC among patients receiving ART in Blantyre. Prior to 2000, coverage by the 
registry was restricted to the immediate vicinity of Blantyre city and was mostly pathology-based. 
Therefore, HIV patients who received a clinical cancer diagnosis only or those who were diagnosed with a 
NADC outside of QECH prior to starting ART were not captured by the registry. Clinically diagnosed ADC, 
which are used for WHO staging of HIV/AIDS, in principle would still be recorded in the ART cohorts, 
therefore prevalent ADC are less likely to be underreported. The 2007-2010 period is not able to capture 
late incident NADC developing after diagnosis year 2010, even though prospective follow-up in the ART 
cohorts extends beyond 2010. Therefore, the later period of the study captures only prevalent and early 
incident NADC diagnoses. Consequently, incidence rates of late incident cancer may be underreported 
for persons entering the cohorts during the later years of study.   
In terms of generalizability, our study includes ART cohorts from centers of excellence for HIV care 
in the two largest cities in Malawi. The clinics are also adjacent to tertiary centers where the majority of 
oncology care is delivered within the country. Our findings may not be representative of ART delivery and 
cancer care in rural settings. However, public health implications are expected to remain generalizable to 
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patients receiving ART at large clinics in Malawi. Findings in our descriptive epidemiological work did not 
address confounding by cancer treatment nor by behavioral risk factors such as smoking or alcohol 
abuse, since this information was not available. In Malawi, surveys report 14.6% prevalence of heavy 
drinking among men and 1.4% among women, and 18.0 % prevalence of tobacco smoking among men 
and 1.2% among women.195, 196 However, the prevalence of these risk factors specifically among people 
living with HIV in Malawi has yet to be characterized. The study did not have data with which to examine 
cohort-level cancer screening effects for cervical cancer and KS. 
There were contextual limitations to conducting this study in a low-income country. We were limited 
in our ability to correlate CD4 count and HIV viral load with cancer incidence, with consequently reduced 
ability to study important clinical predictors of cancer incidence. Limited CD4 count data and no HIV RNA 
data were available during the period of our study reflecting practice within the Malawi national HIV 
program. CD4 count was historically restricted to stage 1 and 2 patients who were not clinically eligible for 
ART (e.g. stages 3 and 4). For Queen Elizabeth Central Hospital prior to 2011, CD4 counts were not 
captured in the electronic monitoring system and therefore were not available for analysis. Routine HIV 
RNA monitoring in Malawi did not begin until 2011. Viral load is available for a small number of patients, 
thereby precluding its evaluation in our analyses. Due to the high cost of HIV RNA assessment ($20-60 
per test), WHO guidelines historically have not recommended routine viral load testing among persons 
already on ART in low- and middle-income countries. Current WHO guidelines recommend viral load 
testing 6 months after starting ART, and then at 12 months and yearly if people have achieved viral 
suppression 197; Malawi guidelines recommend viral load testing every other year for people receiving 
ART.16 Continued efforts to improve capacity of viral load testing are underway in Malawi, where one in 
five ART patients received at least one viral load test in 2015-2016 and 82%-89% of those tested 
achieved viral suppression.198 Viremia may contribute directly to cancer pathogenesis of KS and NHL, 
and possibly indirectly for virally associated NADCs including HL, anal cancer, and liver cancer .40, 199-202  
Moving forward, understanding the roles of long duration of viremia and viral suppression in cancer 
development may have practical implications for risk stratification among people receiving ART. 
Our ability to detect lymphomas and certain solid tumors such as liver, lung, prostate, and colorectal 
cancers may be limited. These cancer sites may be underdiagnosed even in the general population 
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because the availability of pathology and medical imaging were limited in Malawi during the study period. 
Therefore, these types of cancers in the registry are likely an underestimate of the true burden of disease 
both in the overall population and in our study population. The cancer incidence rates we observed in our 
study may represent the “tip of the iceberg” of the disease burden which is truly occurring in Malawi. For 
similar reasons, detailed histology and cancer subtyping were not available for analysis. Despite these 
limitations, it is important to emphasize that the Malawi cancer registry remains one of the best regional 
resources for population-based data contributing to IARC global burden of disease estimates, in a part of 
the world where deficits in high-quality cancer registration have been abundantly described. 106, 203 
 Conclusions and future directions 
We implemented a healthcare data linkage in a low-resource setting to construct a de novo resource 
for public health research. We built a process for integrating health information from two independent 
sources, EMRs and a disease registry, and studied the validity and performance of this process in the 
field. Our approach uses evidence from observational HIV cohorts at high-volume clinics and locally 
collected cancer outcomes. In alignment with this approach, our findings reflect actual clinical practice 
and the realities of health systems in Malawi.  
Results from the linkage have several implications for strengthening health systems in Malawi. First, 
the data linkage identified little overlap of KS and cervical cancer diagnoses between HIV EMRs and the 
Malawi cancer registry. Updating Malawi’s cancer surveillance design to include sentinel HIV clinics within 
a small, yet well-enumerated geographic region such as Blantyre or Lilongwe, would more thoroughly 
capture the full burden of ADC that are being diagnosed primarily in HIV point-of-care clinics, not district 
hospitals. Ideally, such a design would involve more direct data sharing through data transfers directly 
from EMR databases at large clinics and paper-based, cross-sectional collection at smaller clinics. 
Additionally, future cancer surveillance could incorporate KS diagnoses captured by the national ART 
registry, which is still being refined. Further harmonizing EMRs and paper-based records that feed into 
the contemporary ART national registry is important if the ART registry is to be used for public health 
research. At the time of our study, the Malawi ART registry was fraught with non-unique national IDs and 
duplication of patient records, among other issues. Our findings also emphasize improving the collection 
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of accurate and complete personal identifiers and demographics in EMRs, as well as the cancer registry, 
so long as this is not done at the expense of maintaining high quality clinical information.  
Missing data in the EMR and cancer registry reduced performance of linkage algorithms. There are 
novel analytic approaches that could potentially strengthen the performance of algorithms in our 
subsequent work. An algorithm that uses distance imputation between two linkage fields, rather than 
imputation of missing values, estimates the extent of agreement or disagreement of two linkage fields 
when one or both are missing.204 This type of imputation uses the records with full data to calculate a 
conditional probability of agreement of the fields with missing data in a given record pair, given similarity 
across the other linkage fields. A different approach may consider an algorithm that uses weight 
redistribution, which removes the weight assigned to the variable with missingness and redistributes it 
across the other linkage fields that are complete.204  
We used the linked HIV-cancer dataset to describe the cancer burden among people receiving ART 
during the period of ART scale-up in Malawi. Further studies should be conducted to both validate and 
expand upon the descriptive epidemiology of cancer occurrence among contemporary HIV populations in 
Malawi. Malawi’s national ART program is still young and our work focused on the period of early scale-
up when eligibility for therapy was restricted to persons with very advanced HIV. Future work may update 
the data linkage so that contemporary HIV populations who are initiating therapy under expanded 
eligibility guidelines may be studied. Since 2010, revised guidelines now recommend starting therapy at 
higher CD4 counts and lifelong therapy for HIV-infected pregnant women regardless of HIV stage or CD4 
count.  
Furthermore, contemporary data from QECH and LT include information on CD4 levels and HIV viral 
load which may be used to explore associations with cancer development and replicate findings from 
Western settings. Associations between immunodeficiency and viremia have been described in European 
and American populations, where low CD4 counts are associated with virally- related NADCs 38-41, and 
long duration of immune suppression increases risk of HPV-related cancers.43, 4 HIV viremia is associated 
with increased risk of NHL205, 206, anal cancer200-202, Hodgkin lymphoma200, 201 . Describing associations 
between clinically relevant biomarkers and cancer development, specifically in Malawian ART patient 
populations, may be useful for cancer risk stratification during a time frame of current WHO guidelines.197 
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Our study is a baseline against which to monitor temporal trends and to compare with the 
contemporary burden of cancer among people who are starting therapy at earlier stages of HIV, when 
ART is more likely to have a substantial impact on cancer incidence. Descriptive epidemiological data, 
specifically focusing among people living with HIV, is critical for decision makers at the Malawi Ministry of 








APPENDIX A. STANDARDIZED INCIDENCE RATIOS 
Appendix A Table 1. Standardized incidence ratios for AIDS-defining cancers (2007-2010 only) 

















sarcoma 1224.4 36.2 14.5 (13.3, 15.6) 524.0 (482.4, 565.5)  148.2 66.8 1.0 (0.7, 1.3) 67.2 (47.1, 87.3) 
            
Cervical cancer 39.4 54.6 0.4 (0.2, 0.6) 20.3 (8.8, 31.8)  106.6 73.1 0.7 (0.4, 1.02) 
51.21 (27.6, 
74.9) 
            
NHL 2.0007 9.0 0.4 (0, 1.2) 3.76 (0, 11.2)   0 22.004 0   0 (0,0) 
SIR: Standardized Incidence Ratio, sex-age indirect standardization with population weights from the 2008 census, using central and southern regions of Malawi 
as referent populations for LT and QECH, respectively 
LT: Lighthouse Trust 
QECH: Queen Elizabeth Central Hospital 
NHL: Non-Hodgkin Lymphoma 
Ancillary analyses will evaluate whether risk of NADC among ART users is elevated relative to the general population of Malawi. To date, we 
conducted preliminary analysis of standardized incidence ratios (SIRs) for KS and cervical cancer. We used sex-age indirect standardization with 
population weights from the 2008 census, with central and southern regions of Malawi as referent populations for LT and QECH, respectively. 
Compared to the general population, we observed elevated risk of KS among ART users at LT (SIR=14.5, 95%CI 13.3, 15.6) but paradoxically, 
not at QECH (SIR=1.0, 95%CI 0.7, 1.3). We observed a reduced risk for cervical cancer among ART users in both cohorts (LT SIR=0.4, 95%CI 
0.2, 0.6; QECH SIR=0.7, 95%CI 0.4, 1.02).
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APPENDIX B. CUMULATIVE RISK OF CANCER AMONG NEW ART USERS  
We examined the cumulative risk of cancer in the presence of 1) competing risks and, 2) the large 
proportion of individuals who already have the disease at the start of follow-up. Ignoring high baseline 
prevalence of AIDS-defining cancers KS and cervical cancer, which are clinical indications to initiate ART, 
may lead to underestimation of the true risk of developing cancer among ART users. The overall age-sex-
adjusted cancer incidence was calculated using direct standardization. We used a modified Kaplan-Meier 
approach to estimate adjusted cumulative incidence (ACI) without conditioning on event-free status at 
baseline enrollment and accounting for competing risk of death. The ACI was estimated at index ages 20-
29, 30-39, and 40-49 years assuming a scenario of the youngest age of cancer diagnosis at 20 years and 
age-sex-specific cancer prevalence derived from the cohort. Age in discrete years was used as the time 
scale, and number of years at risk were a function of the width of the age group. Survival time was 
censored at the last date of contact or administratively on 31/12/2010. 
 
Appendix B Table 1. Cancer prevalence at ART start (Lighthouse Trust) 
 
Ages 20-29 years Ages 30-39 years Ages 40-49 years 
  Naïve ART 
users (N) 
Prevalence 









any cancer  
(%) 
Prevalence             
Men 1028 19.2 2969 21.6 1592 22.7 
Women 3160 14.1 3642 16.2 1279 18.8 
  
  At risk (N) Person-years   
at risk‡ 
At risk (N) Person-years 
at risk‡ 
At risk (N) Person-years  
at risk‡ 
Incidence             
Men 831 1218 2328 3524 1231 1939 
Women 2714 4203 3051 4887 1279 1637 
† prevalence of any cancer at cohort enrollment. Kaposi sarcoma and cervical cancer account for >98% of prevalent 
malignancies. 







Appendix B Table 2. Cumulative incidence of ever cancer among ART users, Lighthouse Trust 
 
+10 years +10 years 
 
Estimated risk (%) 
Adjusting for competing risk 
and baseline prevalence of 
cancer  
(95%CI) Estimated risk (%)  
Adjusting for 
competing risk only 
(95%CI)  
Men, Current Age   
  
20 25.3 (21.4, 29.1) 8.8 (4.6, 13.0) 
30 28.2 (26.4, 30.1) 9.2 (7.5, 10.9) 
40 28.8 (25.8, 30.4) 7.7 (5.9, 9.4) 
Women, Current Age 
   
20 21.4 (19.4, 23.5) 9.2 (7.5, 10.9) 
30 23.1 (21.6, 24.6) 7.7 (5.9, 9.4) 
40 23.6 (21.3, 6.0) 9.2 (7.5, 10.9) 
 
 
Results: In Appendix B Appendix B Table 2, estimated risk is the age-conditional probability of 
having or developing cancer (i.e. ever). In the left column, for a 20-year old man who started ART at 
Lighthouse Trust during 2007-2010, the risk of already having or developing cancer by age 29 was 
25.3%.   In the right column, without considering baseline prevalence or setting the baseline hazard to 0, 
our estimate reduces to the cumulative incidence adjusting only for competing risk.   
 





We plan to extend this work to the QECH cohort, and also parse cumulative incidence for ADC and 
NADC groups, while simultaneously accounting for competing risks and prevalence of cancer at time of 
clinic enrollment. Our preliminary results estimated the probability of having or developing cancer over a 
10-year time horizon, given a specific age at ART start. For example, we show that for a 20-year old man, 
the risk of already having or developing cancer by age 29 was 25% and 21% for a 20-year old woman. By 
age 30, the ACI increases to 28% for men and 23% for women. Our estimates of ACI use the most 
current age-specific cancer incidence rates in a population of young ART users, are less susceptible to 
historic calendar trends in cancer incidence, and may be more reflective of risk experienced by those 
alive today. On a policy level, cumulative risk estimates are important to plan for the future burden of 
cancer while also accounting for the current burden of disease.
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APPENDIX C. TEMPORAL TRENDS IN INCIDENCE OF KAPOSI SARCOMA 
For KS and cervical cancer, incidence rate ratios (IRR) were calculated for calendar period of clinic 
enrollment categorized as 2000-2003 (limited ART), 2004-2006 (early national ART scale-up), 2007-2010 
(later national ART scale-up) to describe secular trends in cancer incidence at QECH during ART scale-
up. To examine temporal trends in cancer incidence, an update to the linkage with new cancer registry 
data collected in Blantyre from 2011 through 2015 will be conducted. This will enable a trend analysis of 
incidence rates comparing the 2007-2010 period to the 2011-2015 period at QECH in Blantyre. A 
preliminary trend analysis was conducted for the 2000-2010 period but results are subject to calendar 
artifacts in the early cancer registry design and therefore should be interpreted with reservation.  
AIDS-defining cancers across calendar period 
The trend of KS incidence among ART users at QECH was not linear across calendar period of 
enrollment: IR peaked in 2004-2006 at 661·1 (95%CI: 554·5, 788·0), with most cases diagnosed among 
stage 4 patients, followed by a 76% decline in incidence by 2007-2010 (IRR=0·24; 95%CI: 0·11, 0·51; 
Appendix C Table 1). At the same time, a shift in WHO stage was noted across calendar periods: in 
2000-2003,  two-thirds of patients initiated therapy at clinical stage 1 or 2; by 2004-2006, this shifted to 
79% at clinical stages 3 or 4. By 2007-2010, approximately half of patients were stage 3 or 4 and this was 
distribution was similar to LH during the same period (Appendix C Table 2; Appendix C Figure 1).  
At QECH, KS incidence among men during 2004-2006 (IR: 1083; 96%CI: 863, 1360) was 
comparable to that observed at LH during 2007-2010 (IRR: 1.11; Appendix C Table 1). Among women, 
the IR of KS during 2004-2006 was less than half that of men (IR: 418·4; 96%CI: 317·1, 552·0). 
The calendar trend in KS incidence is likely an artifact of both evolving KS screening at QECH and a 
calendar effect of underascertainment by the registry. Historically, a large proportion of KS cases from 
QECH were diagnosed in the out-patient department (OPD) and referred to an external palliative care 
center (Tiyanjane), both of which were not primary sources of information during the 2000-2003 
expansion of population-based cancer registration. Accordingly, the cancer registry recorded a surge of 
KS cases once the OPD was added as a datasource in 2003 (Dzamalala personal communication). 
Furthermore, in Blantyre, suspected KS patients are often referred to dermatology clinic (LEPRA) for 
diagnostic confirmation rather than pathology. Once confirmed, cases are in turn referred directly to 
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palliative care or again to oncology. Given the fragmented nature of medical record keeping in low-
resource settings and under-resourced healthcare system, a substantial proportion of KS cases may be 
lost along this chain of referrals, and subsequently invisible to public health surveillance activities by the 
registry. Calendar trends in KS incidence recorded during the early years of the registry should be 







Appendix C Table 1. Kaposi sarcoma and cervical cancer incidence rates by WHO clinical stage, early versus late timing of cancer diagnosis, and 
calendar period of ART initiation 
 QECH 2000-2003  QECH 2004-2006  QECH 2007-2010  LH 2007-2010 
 IR (95% CI ) 
IRR 
(95%CI) IR (95% CI ) 
IRR 
(95%CI) IR (95% CI ) 
IRR 
(95%CI) IR (95% CI ) 
IRR 
(95%CI) 
Both sexes             
All stages 224.1 (106.8, 470.0) 
0.34 
(0.16, 0.72) 661.1 (554.5, 788.0) 1. 156.9 (117.1, 209.6) 
0.24 
(0.11, 0.51) 1204.2 (1111.7, 1304.3) 1.82 
stage 1 or 2 - -  16.4 (5.4, 50.1) 1. 62.8 (39.6, 99.5) 3.82 336.7 (289.5, 391.6) 20.48 
early incident - -  - -  55.0 (33.6, 89.9) 7.05 233.6 (194.9, 280.1)  
late incident - -  16.5 (5.4, 50.4)  7.8 (2.1, 28.8)  103.2 (78.6, 135.6)  
stage 3 20.5 (1.7, 243.8) 0.35 59.1 (32.7, 106.6) 1. 60.7 (38.0, 96.9) 1.03 177.7 (144.3, 218.8) 3.01 
early incident 20.4 (1.7, 242.7)  18.0 (6.2, 52.4)  46.3 (27.1, 79.2) 3.23 155.2 (124.2, 193.9)  
late incident - -  41.1 (20.3, 83.4)  14.4 (5.5, 37.6)  22.6 (12.6, 40.6)  
stage 4 207.0 (95.2, 449.9) 0.35 589.8 (489.4, 710.8) 1. 33.5 (17.8, 62.9) 0.16 242.1 (202.6, 289.4) 0.41 
early incident - -  481.2 (391.4, 591.6)  29.5 (15.1, 57.8) 7.57 185.2 (151.1, 227.1)  
late incident 207.6 (95.5, 451.2)  107.8 (69.7, 166.8)  3.9 (0.6, 24.7)  57.0 (39.5, 82.4)  
Men             
All stages 332.7 (135.6, 816.2) 0.31 1083.5 (863.3, 1360.0) 1. 232.1 (159.7, 337.4) 0.21 1207.6 (1064.3, 1370.2) 1.11 
stage 1 or 2 - -  14.7 (2.1, 103.4) 1. 65.8 (32.6, 132.8) 4.49 393.4 (315.3, 490.9)  
early incident - -  14.7 -  46.8   281.2 (216.4, 365.4)  
late incident - -  - -  19.0   112.4 (74.3, 170.1)  
stage 3 43.7 (3.7, 519.8) 0.67 65.1 (25.7, 164.4) 1. 103.4 (59.1, 181.1) 1.59 236.2 (177.5, 314.3)  
early incident  (0.0, 0.0)  14.7   - -  212.1 (156.9, 286.8)  
late incident - -  50.5 (17.6, 144.7)  26.7 (8.9, 80.4)  24.2 (9.9, 59.0)  
stage 4 289.0 (110.3, 756.9) 0.29 1003.8 (792.7, 1271.1) 1. 62.9 (30.7, 129.0) 0.06 568.5 (472.9, 683.4) 0.57 
early incident - -  - -  53.4 (24.5, 116.5)  425.8 (344.2, 526.8)  
late incident 291.2 (111.2, 762.8)  - -  9.5 (1.5, 60.3)  142.9 (99.0, 206.3)  
Women      0.3       
All stages 132.0 (35.5, 490.1) 0.32 418.4 (317.1, 552.0) 1. 104.3 (65.6, 166.0) 0.25 1201.9 (1084.0, 1332.5) 2.87 
stage 1 or 2 - -  17.5 (4.5, 67.8) 1. 60.5 (32.9, 111.4) 3.47 299.0 (243.1, 367.7) 17.13 
early incident - -  17.6 -  60.6 (33.0, 111.6)  202.1 (157.1, 259.9)  
late incident - -  - -  - -  97.1 (67.6, 139.7)  
stage 3 - -  54.9 (25.6, 118.0) 1. 30.9 (13.2, 72.6) 0.56 138.9 (102.5, 188.1) 2.53 
early incident - -  19.8 (5.5, 71.1)  19.8 (5.5, 71.1)  117.3 (84.3, 163.3)  
late incident - -  35.6 (13.7, 92.3)  5.8 (0.8, 41.7)  21.6 (10.0, 46.7)  
stage 4 132.0 (35.5, 502.9) 0.38 346.0 (255.1, 469.3) 1. 12.9 (3.5, 48.3) 0.04 25.4 (12.5, 51.7) 0.07 
early incident - -  297.3 (213.7, 413.5)  12.9 (3.5, 48.4)  25.4 (12.5, 51.7)  
late incident 132.0 (35.5, 502.9)  51.3 (23.2, 113.5)  - -  - -  
IR: incidence rates per 100,000 person-years on ART, direct standardized for sex-age categories using combined cohorts as standard population 
95% CI : 95% Confidence Interval 
IRR: incidence rate ratio 
Calendar periods include  2000-2003 (limited availability fee-for-service ART, Blantyre only), 2004-2006 (early period national scale-up of ART access), 2007-2010 












  LH 
 2000-2003 2004-2006 2007-2010   2007-2010 
WHO stage N  Py % Py N  Py % Py N  Py % Py N  Py % Py 
stage 1 or 2 267 2059 
66% 
 
 708 3768 20% 2933 12965 45% 4197 17693 35% 
stage 3 128 878 28% 2424 12217 65% 3150 13026 45% 4919 19362 39% 
stage 4 27 183 6% 654 2674 14% 759 2618 9% 1367 4854 10% 
Unknown/Not 
applicable 0 0.0 0% 3 28 0% 138 412 1% 1981 8070 16% 
Total 422 3121 
  
  3789 18689 
  
  6980 29022 
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